1
|
Sacher J, Zsido RG, Barth C, Zientek F, Rullmann M, Luthardt J, Patt M, Becker GA, Rusjan P, Witte AV, Regenthal R, Koushik A, Kratzsch J, Decker B, Jogschies P, Villringer A, Hesse S, Sabri O. Increase in serotonin transporter binding in patients with premenstrual dysphoric disorder across the menstrual cycle: a case-control longitudinal neuroreceptor ligand PET imaging study. Biol Psychiatry 2023:S0006-3223(23)00005-7. [PMID: 36997451 DOI: 10.1016/j.biopsych.2022.12.023] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/29/2022] [Revised: 11/30/2022] [Accepted: 12/30/2022] [Indexed: 01/20/2023]
Abstract
BACKGROUND Premenstrual dysphoric disorder (PMDD) disrupts the lives of millions of people each month. The timing of symptoms suggests that hormonal fluctuations play a role in the pathogenesis. Here, we tested whether a heightened sensitivity of the serotonin system to menstrual cycle phase underlies PMDD, assessing the relationship of serotonin transporter (5-HTT) changes with symptom severity across the menstrual cycle. METHODS In this longitudinal case-control study, we acquired 118 [11C]DASB positron emission tomography scans measuring 5-HTT nondisplaceable binding potential (BPND) in 30 patients with PMDD and 29 controls during 2 menstrual cycle phases (periovulatory, premenstrual). The primary outcome was midbrain and prefrontal cortex 5-HTT BPND. We tested whether BPND changes correlated with depressed mood. RESULTS Linear mixed effects modeling (significant group × time × region interaction) showed a mean increase of 18% in midbrain 5-HTT BPND (mean [SD] periovulatory = 1.64 [0.40], premenstrual = 1.93 [0.40], delta = 0.29 [0.47]: t29 = -3.43, p = .0002) in patients with PMDD, whereas controls displayed a mean 10% decrease in midbrain 5-HTT BPND (periovulatory = 1.65 [0.24] > premenstrual = 1.49 [0.41], delta = -0.17 [0.33]: t28 = -2.73, p = .01). In patients, increased midbrain 5-HTT BPND correlated with depressive symptom severity (R2 = 0.41, p < .0015) across the menstrual cycle. CONCLUSIONS These data suggest cycle-specific dynamics with increased central serotonergic uptake followed by extracellular serotonin loss underlying the premenstrual onset of depressed mood in patients with PMDD. These neurochemical findings argue for systematic testing of pre-symptom-onset dosing of selective serotonin reuptake inhibitors or nonpharmacological strategies to augment extracellular serotonin in people with PMDD.
Collapse
|
2
|
Griebsch NI, Kern J, Hansen J, Rullmann M, Luthardt J, Helfmeyer S, Dekorsy FJ, Soeder M, Hankir MK, Zientek F, Becker GA, Patt M, Meyer PM, Dietrich A, Blüher M, Ding YS, Hilbert A, Sabri O, Hesse S. Central Serotonin/Noradrenaline Transporter Availability and Treatment Success in Patients with Obesity. Brain Sci 2022; 12:brainsci12111437. [PMID: 36358364 PMCID: PMC9688491 DOI: 10.3390/brainsci12111437] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2022] [Revised: 09/30/2022] [Accepted: 10/13/2022] [Indexed: 12/04/2022] Open
Abstract
Serotonin (5-hydroxytryptamine, 5-HT) as well as noradrenaline (NA) are key modulators of various fundamental brain functions including the control of appetite. While manipulations that alter brain serotoninergic signaling clearly affect body weight, studies implicating 5-HT transporters and NA transporters (5-HTT and NAT, respectively) as a main drug treatment target for human obesity have not been conclusive. The aim of this positron emission tomography (PET) study was to investigate how these central transporters are associated with changes of body weight after 6 months of dietary intervention or Roux-en-Y gastric bypass (RYGB) surgery in order to assess whether 5-HTT as well as NAT availability can predict weight loss and consequently treatment success. The study population consisted of two study cohorts using either the 5-HTT-selective radiotracer [11C]DASB to measure 5-HTT availability or the NAT-selective radiotracer [11C]MRB to assess NAT availability. Each group included non-obesity healthy participants, patients with severe obesity (body mass index, BMI, >35 kg/m2) following a conservative dietary program (diet) and patients undergoing RYGB surgery within a 6-month follow-up. Overall, changes in BMI were not associated with changes of both 5-HTT and NAT availability, while 5-HTT availability in the dorsal raphe nucleus (DRN) prior to intervention was associated with substantial BMI reduction after RYGB surgery and inversely related with modest BMI reduction after diet. Taken together, the data of our study indicate that 5-HTT and NAT are involved in the pathomechanism of obesity and have the potential to serve as predictors of treatment outcomes.
Collapse
Affiliation(s)
| | - Johanna Kern
- Department of Nuclear Medicine, University of Leipzig, 04103 Leipzig, Germany
| | - Jonas Hansen
- Integrated Research and Treatment Center Adiposity Diseases, 04103 Leipzig, Germany
- Department of Pneumology, Jena University Hospital, University of Jena, 07747 Jena, Germany
| | - Michael Rullmann
- Department of Nuclear Medicine, University of Leipzig, 04103 Leipzig, Germany
| | - Julia Luthardt
- Department of Nuclear Medicine, University of Leipzig, 04103 Leipzig, Germany
| | - Stephanie Helfmeyer
- Integrated Research and Treatment Center Adiposity Diseases, 04103 Leipzig, Germany
- Institute of Nutritional Sciences, Friedrich-Schiller-Universität Jena, 07743 Jena, Germany
| | - Franziska J. Dekorsy
- Department of Nuclear Medicine, University Hospital, Ludwig Maximilian University of Munich, 81377 Munich, Germany
| | - Marvin Soeder
- Integrated Research and Treatment Center Adiposity Diseases, 04103 Leipzig, Germany
| | - Mohammed K. Hankir
- Department of Experimental Surgery, University Hospital Würzburg, 97080 Würzburg, Germany
| | - Franziska Zientek
- Department of Nuclear Medicine, University of Leipzig, 04103 Leipzig, Germany
- Integrated Research and Treatment Center Adiposity Diseases, 04103 Leipzig, Germany
| | | | - Marianne Patt
- Department of Nuclear Medicine, University of Leipzig, 04103 Leipzig, Germany
| | - Philipp M. Meyer
- Department of Nuclear Medicine, University of Leipzig, 04103 Leipzig, Germany
- Integrated Research and Treatment Center Adiposity Diseases, 04103 Leipzig, Germany
| | - Arne Dietrich
- Integrated Research and Treatment Center Adiposity Diseases, 04103 Leipzig, Germany
- Department of Abdominal, Transplant, Thoracic and Vascular Surgery, University Hospital Leipzig, 04103 Leipzig, Germany
| | - Matthias Blüher
- Medical Department III-Endocrinology, Nephrology, Rheumatology, University of Leipzig Medical Center, Helmholtz Institute for Metabolic, Obesity and Vascular Research (HI-MAG) of the Helmholtz Zentrum München at the University of Leipzig, 04103 Leipzig, Germany
| | - Yu-Shin Ding
- Departments of Radiology and Psychiatry, New York University School of Medicine, New York, NY 10016, USA
| | - Anja Hilbert
- Integrated Research and Treatment Center Adiposity Diseases, 04103 Leipzig, Germany
- Behavioral Medicine Research Unit, Department of Psychosomatic Medicine and Psychotherapy, 04103 Leipzig, Germany
| | - Osama Sabri
- Department of Nuclear Medicine, University of Leipzig, 04103 Leipzig, Germany
| | - Swen Hesse
- Department of Nuclear Medicine, University of Leipzig, 04103 Leipzig, Germany
- Integrated Research and Treatment Center Adiposity Diseases, 04103 Leipzig, Germany
- Correspondence:
| |
Collapse
|
3
|
Tiepolt S, Becker GA, Wilke S, Cecchin D, Rullmann M, Meyer PM, Barthel H, Hesse S, Patt M, Luthardt J, Wagenknecht G, Sattler B, Deuther-Conrad W, Ludwig FA, Fischer S, Gertz HJ, Smits R, Hoepping A, Steinbach J, Brust P, Sabri O. (+)-[ 18F]Flubatine as a novel α4β2 nicotinic acetylcholine receptor PET ligand-results of the first-in-human brain imaging application in patients with β-amyloid PET-confirmed Alzheimer's disease and healthy controls. Eur J Nucl Med Mol Imaging 2021; 48:731-746. [PMID: 32935187 PMCID: PMC8036219 DOI: 10.1007/s00259-020-05029-w] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2020] [Accepted: 09/07/2020] [Indexed: 11/25/2022]
Abstract
PURPOSES We present the first in-human brain PET imaging data of the new α4β2 nicotinic acetylcholine receptor (nAChR)-targeting radioligand (+)-[18F]Flubatine. Aims were to develop a kinetic modeling-based approach to quantify (+)-[18F]Flubatine and compare the data of healthy controls (HCs) and patients with Alzheimer's disease (AD); to investigate the partial volume effect (PVE) on regional (+)-[18F]Flubatine binding; and whether (+)-[18F]Flubatine binding and cognitive test data respective β-amyloid radiotracer accumulation were correlated. METHODS We examined 11 HCs and 9 mild AD patients. All subjects underwent neuropsychological testing and [11C]PiB PET/MRI examination. (+)-[18F]Flubatine PET data were evaluated using full kinetic modeling and regional as well as voxel-based analyses. RESULTS With 270-min p.i., the unchanged parent compound amounted to 97 ± 2%. Adequate fits of the time-activity curves were obtained with the 1 tissue compartment model (1TCM). (+)-[18F]Flubatine distribution volume (binding) was significantly reduced in bilateral mesial temporal cortex in AD patients compared with HCs (right 10.6 ± 1.1 vs 11.6 ± 1.4, p = 0.049; left 11.0 ± 1.1 vs 12.2 ± 1.8, p = 0.046; one-sided t tests each). PVE correction increased not only (+)-[18F]Flubatine binding of approximately 15% but also standard deviation of 0.4-70%. Cognitive test data and (+)-[18F]Flubatine binding were significantly correlated in the left anterior cingulate, right posterior cingulate, and right parietal cortex (r > 0.5, p < 0.05 each). In AD patients, (+)-[18F]Flubatine binding and [11C]PiB standardized uptake value ratios were negatively correlated in several regions; whereas in HCs, a positive correlation between cortical (+)-[18F]Flubatine binding and [11C]PiB accumulation in the white matter was found. No adverse event related to (+)-[18F]Flubatine occurred. CONCLUSION (+)-[18F]Flubatine is a safe and stable PET ligand. Full kinetic modeling can be realized by 1TCM without metabolite correction. (+)-[18F]Flubatine binding affinity was high enough to detect group differences. Of interest, correlation between white matter β-amyloid PET uptake and (+)-[18F]Flubatine binding indicated an association between white matter integrity and availability of α4β2 nAChRs. Overall, (+)-[18F]Flubatine showed favorable characteristics and has therefore the potential to serve as α4β2 nAChR-targeting PET ligand in further clinical trials.
Collapse
Affiliation(s)
- Solveig Tiepolt
- Department of Nuclear Medicine, University of Leipzig, Liebigstraße 18, 04103 Leipzig, Germany
| | - Georg-Alexander Becker
- Department of Nuclear Medicine, University of Leipzig, Liebigstraße 18, 04103 Leipzig, Germany
| | - Stephan Wilke
- Department of Nuclear Medicine, University of Leipzig, Liebigstraße 18, 04103 Leipzig, Germany
| | - Diego Cecchin
- Department of Medicine, University-Hospital of Padova, Via Giustiniani 2, 35128 Padova, Italy
| | - Michael Rullmann
- Department of Nuclear Medicine, University of Leipzig, Liebigstraße 18, 04103 Leipzig, Germany
| | - Philipp M. Meyer
- Department of Nuclear Medicine, University of Leipzig, Liebigstraße 18, 04103 Leipzig, Germany
| | - Henryk Barthel
- Department of Nuclear Medicine, University of Leipzig, Liebigstraße 18, 04103 Leipzig, Germany
| | - Swen Hesse
- Department of Nuclear Medicine, University of Leipzig, Liebigstraße 18, 04103 Leipzig, Germany
| | - Marianne Patt
- Department of Nuclear Medicine, University of Leipzig, Liebigstraße 18, 04103 Leipzig, Germany
| | - Julia Luthardt
- Department of Nuclear Medicine, University of Leipzig, Liebigstraße 18, 04103 Leipzig, Germany
| | - Gudrun Wagenknecht
- Electronic Systems (ZEA-2), Central Institute for Engineering, Electronics and Analytics, Research Centre Juelich, Wilhelm-Johnen-Straße, 52428 Juelich, Germany
| | - Bernhard Sattler
- Department of Nuclear Medicine, University of Leipzig, Liebigstraße 18, 04103 Leipzig, Germany
| | - Winnie Deuther-Conrad
- Helmholtz-Zentrum Dresden-Rossendorf, Research Site Leipzig, Permoserstraße 15, 04318 Leipzig, Germany
| | | | - Steffen Fischer
- Helmholtz-Zentrum Dresden-Rossendorf, Research Site Leipzig, Permoserstraße 15, 04318 Leipzig, Germany
| | - Hermann-Josef Gertz
- Department of Psychiatry, University of Leipzig, Semmelweisstraße 10, 04103 Leipzig, Germany
| | - René Smits
- ABX advanced biochemical compounds GmbH, Heinrich-Gläser-Straße 10, 01454 Radeberg, Germany
| | - Alexander Hoepping
- ABX advanced biochemical compounds GmbH, Heinrich-Gläser-Straße 10, 01454 Radeberg, Germany
| | - Jörg Steinbach
- Helmholtz-Zentrum Dresden-Rossendorf, Bautzener Landstr. 400, 01328 Dresden, Germany
| | - Peter Brust
- Helmholtz-Zentrum Dresden-Rossendorf, Research Site Leipzig, Permoserstraße 15, 04318 Leipzig, Germany
| | - Osama Sabri
- Department of Nuclear Medicine, University of Leipzig, Liebigstraße 18, 04103 Leipzig, Germany
| |
Collapse
|
4
|
Löser J, Luthardt J, Rullmann M, Weise D, Sabri O, Meixensberger J, Hesse S, Winkler D. Striatal dopamine transporter availability and individual clinical course within the 1-year follow-up of deep brain stimulation of the subthalamic nucleus in patients with Parkinson's disease. J Neurosurg 2021:1-7. [PMID: 33607613 DOI: 10.3171/2020.8.jns192740] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2019] [Accepted: 08/07/2020] [Indexed: 11/06/2022]
Abstract
OBJECTIVE Degeneration of dopaminergic neurons in the substantia nigra projecting to the striatum is responsible for the motor symptoms in Parkinson's disease (PD). Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is a well-established procedure to alleviate these symptoms in advanced PD. Yet the mechanism of action, especially the effects of STN-DBS on the availability of striatal dopamine transporter (DAT) as a marker of nigrostriatal nerve cell function, remains largely unknown. The aim of this study was therefore to evaluate whether 1) DAT availability changes within 1 year of STN-DBS and 2) the clinical outcome can be predicted based on preoperative DAT availability. METHODS Twenty-seven PD patients (mean age 62.7 ± 8.9 years; mean duration of illness 13.0 ± 4.9 years; PD subtypes: akinetic-rigid, n = 11; equivalence, n = 13; and tremor-dominant, n = 3) underwent [123I]FP-CIT SPECT preoperatively and after 1 year of STN-DBS. DAT availability as determined by the specific binding ratio (SBR) was assessed by volume of interest (VOI) analysis of the caudate nucleus and the putamen ipsilateral and contralateral to the clinically more affected side. RESULTS Unified Parkinson's Disease Rating Scale (UPDRS) III scores improved significantly (mean preoperative on medication 25.6 ± 12.3, preoperative off medication 42.3 ± 15.2, postoperative on medication/off stimulation 41.4 ± 13.2, and postoperative on medication/on stimulation 16.1 ± 9.4; preoperative on medication vs postoperative on medication/on stimulation, p = 0.006), while the levodopa-equivalent daily dose was reduced (mean preoperative 957 ± 440 mg vs postoperative 313 ± 189 mg, p < 0.001). The SBR did not differ significantly before and 1 year after DBS, regardless of PD subtype. Preoperative DAT availability was not related to the change in UPDRS III score, but the change in DAT availability was significantly correlated with the change in UPDRS III score (contralateral head of the caudate VOI, p = 0.014; contralateral putamen VOI, p = 0.018). CONCLUSIONS Overall, DAT availability did not change significantly after 1 year of STN-DBS. However, on an individual basis, the improvement in UPDRS III score was associated with an increase in DAT availability, whereas DAT availability before STN-DBS surgery did not predict the clinical outcome. Whether a subtype-specific pattern of preoperative DAT availability can become a reliable predictor of successful STN-DBS must be evaluated in larger study cohorts.
Collapse
Affiliation(s)
- Julia Löser
- Departments of1Nuclear Medicine
- 2Neurosurgery, and
- 3Pediatric Surgery, University of Leipzig
| | | | - Michael Rullmann
- Departments of1Nuclear Medicine
- 4Integrated Treatment and Research Centre (IFB) Adiposity Diseases, University of Leipzig; and
| | - David Weise
- 5Department of Neurology, Asklepios Clinic Stadtroda, Germany
| | | | | | - Swen Hesse
- Departments of1Nuclear Medicine
- 4Integrated Treatment and Research Centre (IFB) Adiposity Diseases, University of Leipzig; and
| | | |
Collapse
|
5
|
Tiepolt S, Luthardt J, Patt M, Hesse S, Hoffmann KT, Weise D, Gertz HJ, Sabri O, Barthel H. Early after Administration [11C]PiB PET Images Correlate with Cognitive Dysfunction Measured by the CERAD Test Battery. J Alzheimers Dis 2020; 68:65-76. [PMID: 30636731 DOI: 10.3233/jad-180217] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
BACKGROUND Amyloid-β (Aβ) and [18F]FDG PET are established as amyloid pathology and neuronal injury biomarkers. Early after administration Aβ PET images have the potential to replace [18F]FDG PET images allowing dual biomarker delivery by the administration of a single tracer. For [18F]FDG PET data, a correlation with cognitive performance is known. OBJECTIVE The aim of this study was to investigate whether early after administration [11C]PiB PET data also correlate with cognitive performance. METHODS The early after administration [11C]PiB PET data of 31 patients with cognitive impairment were evaluated. CERAD subtests were summarized to five cognitive domains. The resulting z scores were correlated with the PET data on a voxel- and VOI-based approach. Additional subgroup analyses (MCI versus dementia, Aβ-positive versus Aβ-negative subjects) were performed. RESULTS Significant correlations between cognitive performance and early after administration [11C]PiB PET data were found between left temporo-parietal SUVR and language domain, bilateral occipital as well as left temporal SUVR and executive function, left pre- and postcentral SUVRs, and visuospatial abilities. For the episodic and immediate memory domains, the analysis at the high significance level did not show any correlated cluster, however, the exploratory analysis did. CONCLUSION Our study revealed correlations between deficits in different cognitive domains and regional early after administration [11C]PiB PET data similar to those known from [18F]FDG PET studies. Thus, our data support the assumption that early [11C]PiB PET data have a potential as neuronal injury biomarker. Head-to-head double-tracer studies of larger cohorts are needed to confirm this assumption.
Collapse
Affiliation(s)
- Solveig Tiepolt
- Department of Nuclear Medicine, University of Leipzig, University of Leipzig, Leipzig, Germany
| | - Julia Luthardt
- Department of Nuclear Medicine, University of Leipzig, University of Leipzig, Leipzig, Germany
| | - Marianne Patt
- Department of Nuclear Medicine, University of Leipzig, University of Leipzig, Leipzig, Germany
| | - Swen Hesse
- Department of Nuclear Medicine, University of Leipzig, University of Leipzig, Leipzig, Germany
| | | | - David Weise
- Department of Psychiatry, University of Leipzig, Leipzig, Germany.,Department of Neurology, University of Leipzig, Leipzig, Germany
| | | | - Osama Sabri
- Department of Nuclear Medicine, University of Leipzig, University of Leipzig, Leipzig, Germany
| | - Henryk Barthel
- Department of Nuclear Medicine, University of Leipzig, University of Leipzig, Leipzig, Germany
| |
Collapse
|
6
|
Ulke C, Rullmann M, Huang J, Luthardt J, Becker GA, Patt M, Meyer PM, Tiepolt S, Hesse S, Sabri O, Strauß M. Adult attention-deficit/hyperactivity disorder is associated with reduced norepinephrine transporter availability in right attention networks: a (S,S)-O-[ 11C]methylreboxetine positron emission tomography study. Transl Psychiatry 2019; 9:301. [PMID: 31732713 PMCID: PMC6858438 DOI: 10.1038/s41398-019-0619-y] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/23/2019] [Revised: 09/12/2019] [Accepted: 10/03/2019] [Indexed: 12/22/2022] Open
Abstract
The norepinephrine transporter (NET) has been suggested to play a critical role in attention-deficit/hyperactivity disorder (ADHD). In this prospective controlled study we tested the a-priori-hypothesis that central NET availability is altered in adult ADHD patients compared to healthy controls. Study participants underwent single positron emission tomography-magnetic resonance imaging (PET-MRI). MRI sequences included high resolution T1-MPRAGE data for regions of interest (ROI) delineation and voxel-based morphometry (VBM) and T2-weighted fluid-attenuated inversion-recovery for detection and exclusion of pathological abnormalities. NET availability was assessed by NET-selective (S,S)-O-[11C]methylreboxetine; regional distribution volume ratios (DVR) were calculated based on individual PET-MRI data co-registration and a multi-linear reference tissue model with two constraints (MRTM2; reference region: occipital cortex). VBM analysis revealed no difference in local distribution of gray matter between the 20 ADHD patients (9 females, age 31.8 ± 7.9 years, 488 ± 8 MBq injected activity) and the 20 age-matched and sex-matched control participants (9 females, age 32.3 ± 7.9 years, 472 ± 72 MBq). In mixed-model repeated-measures analysis with NET availability as dependent and ROI as repeated measure we found a significant main effect group in fronto-parietal-thalamic-cerebellar regions (regions on the right: F1,25 = 12.30, p = .002; regions on the left: F1,41 = 6.80, p = .013) indicating a reduced NET availability in ADHD patients. None of the other investigated brain regions yielded significant differences in NET availability between groups after applying a Benjamini-Hochberg correction at a significance level of 0.05. Overall our findings demonstrate the pathophysiological involvement of NET availability in adult ADHD.
Collapse
Affiliation(s)
- Christine Ulke
- Department of Psychiatry and Psychotherapy, University of Leipzig Medical Center, 04103, Leipzig, Germany.
| | - Michael Rullmann
- Department of Nuclear Medicine, University of Leipzig Medical Center, 04103, Leipzig, Germany
| | - Jue Huang
- Department of Psychiatry and Psychotherapy, University of Leipzig Medical Center, 04103, Leipzig, Germany
| | - Julia Luthardt
- Department of Nuclear Medicine, University of Leipzig Medical Center, 04103, Leipzig, Germany
| | - Georg-Alexander Becker
- Department of Nuclear Medicine, University of Leipzig Medical Center, 04103, Leipzig, Germany
| | - Marianne Patt
- Department of Nuclear Medicine, University of Leipzig Medical Center, 04103, Leipzig, Germany
| | - Philipp M Meyer
- Department of Nuclear Medicine, University of Leipzig Medical Center, 04103, Leipzig, Germany
| | - Solveig Tiepolt
- Department of Nuclear Medicine, University of Leipzig Medical Center, 04103, Leipzig, Germany
| | - Swen Hesse
- Department of Nuclear Medicine, University of Leipzig Medical Center, 04103, Leipzig, Germany
| | - Osama Sabri
- Department of Nuclear Medicine, University of Leipzig Medical Center, 04103, Leipzig, Germany
| | - Maria Strauß
- Department of Psychiatry and Psychotherapy, University of Leipzig Medical Center, 04103, Leipzig, Germany
| |
Collapse
|
7
|
Sabri O, Meyer PM, Gräf S, Hesse S, Wilke S, Becker GA, Rullmann M, Patt M, Luthardt J, Wagenknecht G, Hoepping A, Smits R, Franke A, Sattler B, Tiepolt S, Fischer S, Deuther-Conrad W, Hegerl U, Barthel H, Schönknecht P, Brust P. Cognitive correlates of α4β2 nicotinic acetylcholine receptors in mild Alzheimer's dementia. Brain 2019; 141:1840-1854. [PMID: 29672680 PMCID: PMC5972585 DOI: 10.1093/brain/awy099] [Citation(s) in RCA: 47] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2017] [Accepted: 02/19/2018] [Indexed: 12/22/2022] Open
Abstract
In early Alzheimer's dementia, there is a need for PET biomarkers of disease progression with close associations to cognitive dysfunction that may aid to predict further cognitive decline and neurodegeneration. Amyloid biomarkers are not suitable for that purpose. The α4β2 nicotinic acetylcholine receptors (α4β2-nAChRs) are widely abundant in the human brain. As neuromodulators they play an important role in cognitive functions such as attention, learning and memory. Post-mortem studies reported lower expression of α4β2-nAChRs in more advanced Alzheimer's dementia. However, there is ongoing controversy whether α4β2-nAChRs are reduced in early Alzheimer's dementia. Therefore, using the recently developed α4β2-nAChR-specific radioligand (-)-18F-flubatine and PET, we aimed to quantify the α4β2-nAChR availability and its relationship to specific cognitive dysfunction in mild Alzheimer's dementia. Fourteen non-smoking patients with mild Alzheimer's dementia, drug-naïve for cholinesterase therapy, were compared with 15 non-smoking healthy controls matched for age, sex and education by applying (-)-18F-flubatine PET together with a neuropsychological test battery. The one-tissue compartment model and Logan plot method with arterial input function were used for kinetic analysis to obtain the total distribution volume (VT) as the primary, and the specific binding part of the distribution volume (VS) as the secondary quantitative outcome measure of α4β2-nAChR availability. VS was determined by using a pseudo-reference region. Correlations between VT within relevant brain regions and Z-scores of five cognitive functions (episodic memory, executive function/working memory, attention, language, visuospatial function) were calculated. VT (and VS) were applied for between-group comparisons. Volume of interest and statistical parametric mapping analyses were carried out. Analyses revealed that in patients with mild Alzheimer's dementia compared to healthy controls, there was significantly lower VT, especially within the hippocampus, fronto-temporal cortices, and basal forebrain, which was similar to comparisons of VS. VT decline in Alzheimer's dementia was associated with distinct domains of impaired cognitive functioning, especially episodic memory and executive function/working memory. Using (-)-18F-flubatine PET in patients with mild Alzheimer's dementia, we show for the first time a cholinergic α4β2-nAChR deficiency mainly present within the basal forebrain-cortical and septohippocampal cholinergic projections and a relationship between lower α4β2-nAChR availability and impairment of distinct cognitive domains, notably episodic memory and executive function/working memory. This shows the potential of (-)-18F-flubatine as PET biomarker of cholinergic α4β2-nAChR dysfunction and specific cognitive decline. Thus, if validated by longitudinal PET studies, (-)-18F-flubatine might become a PET biomarker of progression of neurodegeneration in Alzheimer's dementia.
Collapse
Affiliation(s)
- Osama Sabri
- Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany
| | - Philipp M Meyer
- Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany
| | - Susanne Gräf
- Department of Psychiatry and Psychotherapy, University of Leipzig, Leipzig, Germany.,Max-Planck-Institute for Human Cognitive and Brain Sciences, Leipzig, Germany
| | - Swen Hesse
- Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany.,Integrated Research and Treatment Centre (IFB) Adiposity Diseases, University of Leipzig, Leipzig, Germany
| | - Stephan Wilke
- Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany
| | | | - Michael Rullmann
- Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany.,Max-Planck-Institute for Human Cognitive and Brain Sciences, Leipzig, Germany.,Integrated Research and Treatment Centre (IFB) Adiposity Diseases, University of Leipzig, Leipzig, Germany
| | - Marianne Patt
- Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany
| | - Julia Luthardt
- Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany
| | - Gudrun Wagenknecht
- Central Institute for Engineering, Electronics and Analytics-Electronic Systems (ZEA-2), Forschungszentrum Jülich, Jülich, Germany
| | | | - Rene Smits
- ABX Advanced Biochemical Compounds GmbH, Radeberg, Germany
| | - Annegret Franke
- Centre for Clinical Trials Leipzig, University of Leipzig, Leipzig, Germany
| | - Bernhard Sattler
- Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany
| | - Solveig Tiepolt
- Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany
| | - Steffen Fischer
- Department of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Research Site Leipzig, Leipzig, Germany
| | - Winnie Deuther-Conrad
- Department of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Research Site Leipzig, Leipzig, Germany
| | - Ulrich Hegerl
- Department of Psychiatry and Psychotherapy, University of Leipzig, Leipzig, Germany
| | - Henryk Barthel
- Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany
| | - Peter Schönknecht
- Department of Psychiatry and Psychotherapy, University of Leipzig, Leipzig, Germany
| | - Peter Brust
- Department of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Research Site Leipzig, Leipzig, Germany
| |
Collapse
|
8
|
Schinke C, Hesse S, Rullmann M, Becker GA, Luthardt J, Zientek F, Patt M, Stoppe M, Schmidt E, Meyer K, Meyer PM, Orthgieß J, Blüher M, Kratzsch J, Ding YS, Then Bergh F, Sabri O. Central noradrenaline transporter availability is linked with HPA axis responsiveness and copeptin in human obesity and non-obese controls. Stress 2019; 22:93-102. [PMID: 30369292 DOI: 10.1080/10253890.2018.1511698] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
The central noradrenaline (NA) stress-response network co-mediates hypothalamic-pituitary-adrenal (HPA) axis activation and arginine-vasopressin (AVP) release. Dysregulation of these systems contributes to stress-related diseases such as human obesity, but their interrelation remains unclear. The study was aimed to test for the first time in vivo whether central noradrenergic activity quantitatively indexed by the availability of the presynaptic NA transporter (NAT) is associated with HPA axis responsiveness as measured with the combined dexamethasone suppression/corticotropin releasing hormone stimulation (dex/CRH) test and copeptin as a surrogate marker of the serum AVP tone in highly obese, otherwise, healthy individuals compared to age- and sex-matched non-obese, healthy controls. In order to assess central NAT availability, positron emission tomography (PET) was applied using the NAT-selective radiotracer S,S-[11C]O-methylreboxetine (MRB) and correlated with curve indicators derived from the dex/CRH test (maximum, MAX, and area under the curve, AUC, for cortisol and adrenocorticotropic hormone, ACTH) as well as with copeptin. In non-obese controls, positive correlations were found between the NAT distribution volume ratios (DVR) of the orbitofrontal cortex (OFC) and the amygdala with the HPA response (OFC: ACTHMAX r = 0.87, p = .001; cortisolMAX r = 0.86, p = .002; amygdala: ACTHMAX r = 0.86, p = .002; cortisolMAX r = 0.79, p = .006), while in obesity, the hypothalamic DVR correlated inversely with the HPA axis response (cortisolMAX, r = -0.66, p = .04) and with copeptin (r = -0.71, p = .02). This association of central NAT availability with HPA axis responsiveness and copeptin suggests a mechanistic interaction between noradrenergic transmission with HPA axis activity and the serum AVP system that differs between non-obese individuals with prefrontal-limbic involvement and obesity with a hypothalamic-centered relationship. Whether the latter finding contributes to obesogenic behavior needs to be further explored.
Collapse
Affiliation(s)
- Christian Schinke
- a Integrated Research and Treatment Center (IFB) Adiposity Diseases , Leipzig University Medical Center , Leipzig , Germany
- b Department of Neurology , University of Leipzig , Leipzig , Germany
- c Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health , Klinik und Hochschulambulanz für Neurologie , Berlin , Germany
| | - Swen Hesse
- a Integrated Research and Treatment Center (IFB) Adiposity Diseases , Leipzig University Medical Center , Leipzig , Germany
- d Department of Nuclear Medicine , University of Leipzig , Leipzig , Germany
| | - Michael Rullmann
- a Integrated Research and Treatment Center (IFB) Adiposity Diseases , Leipzig University Medical Center , Leipzig , Germany
- d Department of Nuclear Medicine , University of Leipzig , Leipzig , Germany
| | | | - Julia Luthardt
- d Department of Nuclear Medicine , University of Leipzig , Leipzig , Germany
| | - Franziska Zientek
- a Integrated Research and Treatment Center (IFB) Adiposity Diseases , Leipzig University Medical Center , Leipzig , Germany
- d Department of Nuclear Medicine , University of Leipzig , Leipzig , Germany
| | - Marianne Patt
- d Department of Nuclear Medicine , University of Leipzig , Leipzig , Germany
| | - Muriel Stoppe
- b Department of Neurology , University of Leipzig , Leipzig , Germany
- e Translational Centre for Regenerative Medicine , University of Leipzig , Leipzig , Germany
| | - Elisa Schmidt
- b Department of Neurology , University of Leipzig , Leipzig , Germany
| | - Klara Meyer
- b Department of Neurology , University of Leipzig , Leipzig , Germany
| | - Philipp M Meyer
- d Department of Nuclear Medicine , University of Leipzig , Leipzig , Germany
| | - Johannes Orthgieß
- b Department of Neurology , University of Leipzig , Leipzig , Germany
| | - Matthias Blüher
- f Department of Internal Medicine , University of Leipzig , Leipzig , Germany
| | - Jürgen Kratzsch
- g Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics , University of Leipzig , Leipzig , Germany
| | - Yu-Shin Ding
- h Departments of Radiology and Psychiatry , New York University School of Medicine , New York , USA
| | - Florian Then Bergh
- b Department of Neurology , University of Leipzig , Leipzig , Germany
- e Translational Centre for Regenerative Medicine , University of Leipzig , Leipzig , Germany
| | - Osama Sabri
- a Integrated Research and Treatment Center (IFB) Adiposity Diseases , Leipzig University Medical Center , Leipzig , Germany
- d Department of Nuclear Medicine , University of Leipzig , Leipzig , Germany
| |
Collapse
|
9
|
Florek L, Tiepolt S, Schroeter ML, Berrouschot J, Saur D, Hesse S, Jochimsen T, Luthardt J, Sattler B, Patt M, Hoffmann KT, Villringer A, Classen J, Gertz HJ, Sabri O, Barthel H. Dual Time-Point [18F]Florbetaben PET Delivers Dual Biomarker Information in Mild Cognitive Impairment and Alzheimer’s Disease. J Alzheimers Dis 2018; 66:1105-1116. [DOI: 10.3233/jad-180522] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Affiliation(s)
- Lisa Florek
- Department of Nuclear Medicine, Leipzig University Hospital, Leipzig, Germany
| | - Solveig Tiepolt
- Department of Nuclear Medicine, Leipzig University Hospital, Leipzig, Germany
| | - Matthias L. Schroeter
- Day Clinic for Cognitive Neurology, Leipzig University Hospital & Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany
| | | | - Dorothee Saur
- Department of Neurology, Leipzig University Hospital, Leipzig, Germany
| | - Swen Hesse
- Department of Nuclear Medicine, Leipzig University Hospital, Leipzig, Germany
- IFB Adiposity Diseases, Leipzig University Hospital, Leipzig, Germany
| | - Thies Jochimsen
- Department of Nuclear Medicine, Leipzig University Hospital, Leipzig, Germany
| | - Julia Luthardt
- Department of Nuclear Medicine, Leipzig University Hospital, Leipzig, Germany
| | - Bernhard Sattler
- Department of Nuclear Medicine, Leipzig University Hospital, Leipzig, Germany
| | - Marianne Patt
- Department of Nuclear Medicine, Leipzig University Hospital, Leipzig, Germany
| | | | - Arno Villringer
- IFB Adiposity Diseases, Leipzig University Hospital, Leipzig, Germany
- Day Clinic for Cognitive Neurology, Leipzig University Hospital & Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany
| | - Joseph Classen
- Department of Neurology, Leipzig University Hospital, Leipzig, Germany
| | | | - Osama Sabri
- Department of Nuclear Medicine, Leipzig University Hospital, Leipzig, Germany
| | - Henryk Barthel
- Department of Nuclear Medicine, Leipzig University Hospital, Leipzig, Germany
| |
Collapse
|
10
|
Hesse S, Müller U, Rullmann M, Luthardt J, Bresch A, Becker GA, Zientek F, Patt M, Meyer PM, Blüher M, Strauß M, Fenske W, Hankir M, Ding YS, Hilbert A, Sabri O. The association between in vivo central noradrenaline transporter availability and trait impulsivity. Psychiatry Res Neuroimaging 2017; 267:9-14. [PMID: 28675825 DOI: 10.1016/j.pscychresns.2017.06.013] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/25/2017] [Revised: 06/19/2017] [Accepted: 06/21/2017] [Indexed: 11/30/2022]
Abstract
The brain noradrenaline (NA) system, particularly NA transporters (NAT), are thought to play an important role in modulating impulsive behavior. Impaired impulsivity is implicated in a variety of neuropsychiatric conditions; however, an in vivo link between central NAT availability and human impulsivity has not been shown. Using positron emission tomography (PET) and S,S-[11C]O-methylreboxetine (MRB), we tested whether NAT availability is associated with this basic behavioral trait based on the Barratt Impulsiveness Scale (BIS-11) in twenty healthy individuals (12 females, 33.8±9.3, 21-52 years of age) with a body mass index (BMI) ranging from 21.7kg/m2 to 47.8kg/m2. Applying both voxel-wise and volume-of-interest (VOI) based analyses, we found that distribution volume ratios (DVR) used as PET outcome measures negatively correlated with BIS-11 total scores in the orbitofrontal cortex (OFC) and in the hippocampus as well as in parts of the cerebellar cortex. These associations however did not remain after correction for multiple testing. Thus, although it appears that low NAT availability is associated with greater scores of impaired behavioral control, this needs to be confirmed in a larger series of individuals with highly impulsive behavior.
Collapse
Affiliation(s)
- Swen Hesse
- Integrated Treatment and Research Centre (IFB) AdiposityDiseases, Leipzig University Medical Centre, Liebigstraße 20, 04103 Leipzig, Germany; Department of Nuclear Medicine, University of Leipzig, Liebigstraße 18, 04103 Leipzig, Germany.
| | - Ulrich Müller
- Department of Psychiatry and Behavioural and Clinical Neuroscience Institute, University of Cambridge Downing Street, Cambridge CB2 3EB, UK
| | - Michael Rullmann
- Department of Nuclear Medicine, University of Leipzig, Liebigstraße 18, 04103 Leipzig, Germany
| | - Julia Luthardt
- Department of Nuclear Medicine, University of Leipzig, Liebigstraße 18, 04103 Leipzig, Germany
| | - Anke Bresch
- Department of Nuclear Medicine, University of Leipzig, Liebigstraße 18, 04103 Leipzig, Germany
| | - Georg-Alexander Becker
- Department of Nuclear Medicine, University of Leipzig, Liebigstraße 18, 04103 Leipzig, Germany
| | - Franziska Zientek
- Integrated Treatment and Research Centre (IFB) AdiposityDiseases, Leipzig University Medical Centre, Liebigstraße 20, 04103 Leipzig, Germany; Department of Nuclear Medicine, University of Leipzig, Liebigstraße 18, 04103 Leipzig, Germany
| | - Marianne Patt
- Department of Nuclear Medicine, University of Leipzig, Liebigstraße 18, 04103 Leipzig, Germany
| | - Philipp M Meyer
- Department of Nuclear Medicine, University of Leipzig, Liebigstraße 18, 04103 Leipzig, Germany
| | - Matthias Blüher
- Integrated Treatment and Research Centre (IFB) AdiposityDiseases, Leipzig University Medical Centre, Liebigstraße 20, 04103 Leipzig, Germany; Department of Internal Medicine, University of Leipzig, Liebigstraße 20, 04103 Leipzig, Germany
| | - Maria Strauß
- Department of Psychiatry and Psychotherapy, University of Leipzig, Semmelweisstraße 10, 04103 Leipzig, Germany
| | - Wiebke Fenske
- Integrated Treatment and Research Centre (IFB) AdiposityDiseases, Leipzig University Medical Centre, Liebigstraße 20, 04103 Leipzig, Germany; Department of Internal Medicine, University of Leipzig, Liebigstraße 20, 04103 Leipzig, Germany
| | - Mohammed Hankir
- Integrated Treatment and Research Centre (IFB) AdiposityDiseases, Leipzig University Medical Centre, Liebigstraße 20, 04103 Leipzig, Germany
| | - Yu-Shin Ding
- Departments of Radiology and Psychiatry, New York University School of Medicine, 550 1st Avenue, New York 10016, USA
| | - Anja Hilbert
- Integrated Treatment and Research Centre (IFB) AdiposityDiseases, Leipzig University Medical Centre, Liebigstraße 20, 04103 Leipzig, Germany; Department of Medical Psychology and Medical Sociology and Department of Psychosomatic Medicine and Psychotherapy, University of Leipzig, Philipp-Rosenthal-Straße 55, 04103 Leipzig, Germany
| | - Osama Sabri
- Integrated Treatment and Research Centre (IFB) AdiposityDiseases, Leipzig University Medical Centre, Liebigstraße 20, 04103 Leipzig, Germany; Department of Nuclear Medicine, University of Leipzig, Liebigstraße 18, 04103 Leipzig, Germany
| |
Collapse
|
11
|
Schinke C, Hesse S, Stoppe M, Meyer K, Schmidt E, Orthgiess J, Bechmann L, Bresch A, Rullmann M, Luthardt J, Sabri O, Blüher M, Kratzsch J, Then Bergh F. Post-dexamethasone serum copeptin corresponds to HPA axis responsiveness in human obesity. Psychoneuroendocrinology 2017; 78:39-47. [PMID: 28167369 DOI: 10.1016/j.psyneuen.2017.01.004] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/13/2016] [Revised: 12/23/2016] [Accepted: 01/04/2017] [Indexed: 12/25/2022]
Abstract
CONTEXT Increased activities of the arginine-vasopressin (AVP) system and the hypothalamic-pituitary-adrenal (HPA) axis were shown to be associated with human obesity, but relationships between these systems in obesity remain unclear. OBJECTIVES To assess HPA axis responsiveness and its relation to serum concentrations of the AVP-surrogate copeptin in subjects with obesity (OB) in comparison to non-obesity controls (NOC). METHODS In a cross-sectional monocentric study, thirty-nine OB (f/m 25/14; age 36.5±10.0years; body mass index, BMI, 41.5±4.7kg/m2) were compared to twenty-two NOC (f/m 12/10; age 35.3±8.5years; BMI 23.1±2.4kg/m2), matched for age and sex. All individuals underwent the combined dexamethasone/CRH test. MAIN OUTCOME MEASURES Plasma ACTH and cortisol curve indicators derived from the dex/CRH test (post-CRH concentrations 30min after 100μg CRH; maximum concentration, MAX; area-under-the-curve, AUC; ACTH/cortisol ratios). Copeptin was assessed in 1500h samples of the dex/CRH test (after 1.5mg of oral dexamethasone, prior to CRH administration). RESULTS Copeptin serum concentrations were higher in OB (median [IQR]: OB 4.62 [2.60-5.88] vs. NOC 3.04 [2.52-4.29] pmol/l, P=0.04). Correspondingly, OB showed higher post-CRH cortisol concentrations (OB: 51.5 [25.9-159.3] vs. NOC: 28.6 [20.0-41.6] nmol/l, P=0.01) and a lower post-CRH ACTH/cortisol ratio (OB: 0.028 [0.016-0.053] vs. NOC: 0.048 [0.034-0.070] pmol/nmol, P<0.01). Serum copeptin was significantly associated with HPA responsiveness in OB (post-CRH ACTH: R=0.42, P<0.01), driven by OB men (post-CRH ACTH: R=0.76, P<0.01, post-CRH cortisol: R=0.64, P=0.02). All associations withstand adjustments for BMI and age. CONCLUSIONS The association between increased copeptin with ACTH and cortisol release suggests a potential mechanistic interaction of the AVP system with HPA activation in human obesity. The relation of copeptin and HPA responsiveness should be further validated in situations with pronounced HPA activation, such as depression or multiple sclerosis.
Collapse
Affiliation(s)
- Christian Schinke
- Department of Neurology, University of Leipzig, Leipzig, Germany; Integrated Research and Treatment Center Adiposity Diseases, University of Leipzig, Leipzig, Germany
| | - Swen Hesse
- Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany; Integrated Research and Treatment Center Adiposity Diseases, University of Leipzig, Leipzig, Germany
| | - Muriel Stoppe
- Department of Neurology, University of Leipzig, Leipzig, Germany; Translational Centre for Regenerative Medicine, University of Leipzig, Leipzig, Germany
| | - Klara Meyer
- Department of Neurology, University of Leipzig, Leipzig, Germany
| | - Elisa Schmidt
- Department of Neurology, University of Leipzig, Leipzig, Germany
| | | | - Lukas Bechmann
- Department of Neurology, University of Leipzig, Leipzig, Germany
| | - Anke Bresch
- Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany
| | - Michael Rullmann
- Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany; Integrated Research and Treatment Center Adiposity Diseases, University of Leipzig, Leipzig, Germany
| | - Julia Luthardt
- Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany
| | - Osama Sabri
- Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany; Integrated Research and Treatment Center Adiposity Diseases, University of Leipzig, Leipzig, Germany
| | - Matthias Blüher
- Integrated Research and Treatment Center Adiposity Diseases, University of Leipzig, Leipzig, Germany; Department of Medicine, University of Leipzig, Leipzig, Germany
| | - Jürgen Kratzsch
- Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University Hospital Leipzig, Leipzig, Germany
| | - Florian Then Bergh
- Department of Neurology, University of Leipzig, Leipzig, Germany; Translational Centre for Regenerative Medicine, University of Leipzig, Leipzig, Germany.
| |
Collapse
|
12
|
Kaller S, Rullmann M, Patt M, Becker GA, Luthardt J, Girbardt J, Meyer PM, Werner P, Barthel H, Bresch A, Fritz TH, Hesse S, Sabri O. Test-retest measurements of dopamine D 1-type receptors using simultaneous PET/MRI imaging. Eur J Nucl Med Mol Imaging 2017; 44:1025-1032. [PMID: 28197685 DOI: 10.1007/s00259-017-3645-0] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2016] [Accepted: 02/02/2017] [Indexed: 12/21/2022]
Abstract
PURPOSE The role of dopamine D1-type receptor (D1R)-expressing neurons in the regulation of motivated behavior and reward prediction has not yet been fully established. As a prerequisite for future research assessing D1-mediated neuronal network regulation using simultaneous PET/MRI and D1R-selective [11C]SCH23390, this study investigated the stability of central D1R measurements between two independent PET/MRI sessions under baseline conditions. METHODS Thirteen healthy volunteers (7 female, age 33 ± 13 yrs) underwent 90-min emission scans, each after 90-s bolus injection of 486 ± 16 MBq [11C]SCH23390, on two separate days within 2-4 weeks using a PET/MRI system. Parametric images of D1R distribution volume ratio (DVR) and binding potential (BPND) were generated by a multi-linear reference tissue model with two parameters and the cerebellar cortex as receptor-free reference region. Volume-of-interest (VOI) analysis was performed with manual VOIs drawn on consecutive transverse MRI slices for brain regions with high and low D1R density. RESULTS The DVR varied from 2.5 ± 0.3 to 2.9 ± 0.5 in regions with high D1R density (e.g. the head of the caudate) and from 1.2 ± 0.1 to 1.6 ± 0.2 in regions with low D1R density (e.g. the prefrontal cortex). The absolute variability of the DVR ranged from 2.4% ± 1.3% to 5.1% ± 5.3%, while Bland-Altman analyses revealed very low differences in mean DVR (e.g. 0.013 ± 0.17 for the nucleus accumbens). Intraclass correlation (one-way, random) indicated very high agreement (0.93 in average) for both DVR and BPND values. Accordingly, the absolute variability of BPND ranged from 7.0% ± 4.7% to 12.5% ± 10.6%; however, there were regions with very low D1R content, such as the occipital cortex, with higher mean variability. CONCLUSION The test-retest reliability of D1R measurements in this study was very high. This was the case not only for D1R-rich brain areas, but also for regions with low D1R density. These results will provide a solid base for future joint PET/MRI data analyses in stimulation-dependent mapping of D1R-containing neurons and their effects on projections in neuronal circuits that determine behavior.
Collapse
Affiliation(s)
- Simon Kaller
- Department of Nuclear Medicine, University of Leipzig, Liebigstrasse 18, D-04103, Leipzig, Germany
| | - Michael Rullmann
- Department of Nuclear Medicine, University of Leipzig, Liebigstrasse 18, D-04103, Leipzig, Germany.,Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany
| | - Marianne Patt
- Department of Nuclear Medicine, University of Leipzig, Liebigstrasse 18, D-04103, Leipzig, Germany
| | - Georg-Alexander Becker
- Department of Nuclear Medicine, University of Leipzig, Liebigstrasse 18, D-04103, Leipzig, Germany
| | - Julia Luthardt
- Department of Nuclear Medicine, University of Leipzig, Liebigstrasse 18, D-04103, Leipzig, Germany
| | - Johanna Girbardt
- Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany
| | - Philipp M Meyer
- Department of Nuclear Medicine, University of Leipzig, Liebigstrasse 18, D-04103, Leipzig, Germany
| | - Peter Werner
- Department of Nuclear Medicine, University of Leipzig, Liebigstrasse 18, D-04103, Leipzig, Germany
| | - Henryk Barthel
- Department of Nuclear Medicine, University of Leipzig, Liebigstrasse 18, D-04103, Leipzig, Germany
| | - Anke Bresch
- Department of Nuclear Medicine, University of Leipzig, Liebigstrasse 18, D-04103, Leipzig, Germany
| | - Thomas H Fritz
- Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany.,Institute for Psychoacoustics and Electronic Music (IPEM), University of Gent, Technicum Blok 2, Sint-Pietersnieuwstraat 41, 9000, Ghent, Belgium
| | - Swen Hesse
- Department of Nuclear Medicine, University of Leipzig, Liebigstrasse 18, D-04103, Leipzig, Germany. .,Integrated Research and Treatment Centre (IFB) Adiposity Diseases, Leipzig University Medical Centre, Leipzig, Germany.
| | - Osama Sabri
- Department of Nuclear Medicine, University of Leipzig, Liebigstrasse 18, D-04103, Leipzig, Germany
| |
Collapse
|
13
|
Bresch A, Rullmann M, Luthardt J, Becker GA, Reissig G, Patt M, Ding YS, Hilbert A, Sabri O, Hesse S. Emotional eating and in vivo norepinephrine transporter availability in obesity: A [ 11 C]MRB PET pilot study. Int J Eat Disord 2017; 50:152-156. [PMID: 27611116 DOI: 10.1002/eat.22621] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/07/2016] [Revised: 08/08/2016] [Accepted: 08/10/2016] [Indexed: 01/03/2023]
Abstract
OBJECTIVE Emotional eating (EE) has been linked to norepinephrine dysfunction. Therefore, we aimed to investigate the relationship between EE and norepinephrine transporter (NET) availability. METHOD Ten severely obese individuals (body mass index (BMI) 42.4 ± 3.7 kg/m2 ) and ten non-obese, healthy controls (BMI 23.9 ± 2.5 kg/m2 ) matched for age and sex were studied using (S,S)-[11 C]-O-methylreboxetine ([11 C]MRB) positron emission tomography (PET). Kinetic modeling of regional tissue time activity curves was performed using multilinear reference tissue model 2 (MRTM2, with the occipital cortex as a reference region) to estimate binding potential based on individual PET-MR coregistration. To test for associations of EE and NET availability, participants completed the EE subscale of the Dutch Eating Behavior Questionnaire before scanning. RESULTS Obese individuals and non-obese, healthy controls did not significantly differ regarding EE scores and regional NET availability. For obese individuals only, correlative data analyses pointed to a sinoidal distribution pattern as a higher degree of EE related to lower NET availability in the locus coeruleus and to higher NET availability in the left thalamus. DISCUSSION These results indicate that central in vivo NET availability is altered in EE of individuals with obesity. © 2016 Wiley Periodicals, Inc.(Int J Eat Disord 2017; 50:152-156).
Collapse
Affiliation(s)
- A Bresch
- Department of Nuclear Medicine, Leipzig, Germany
| | - M Rullmann
- Department of Nuclear Medicine, Leipzig, Germany.,Integrated Treatment and Research Centre (IFB) Adiposity Diseases, Leipzig University Medical Center, Leipzig, Germany
| | - J Luthardt
- Department of Nuclear Medicine, Leipzig, Germany
| | - G A Becker
- Department of Nuclear Medicine, Leipzig, Germany
| | - G Reissig
- Department of Nuclear Medicine, Leipzig, Germany
| | - M Patt
- Department of Nuclear Medicine, Leipzig, Germany
| | - Y-S Ding
- Department of Radiology, New York University School of Medicine, New York, New York.,Department of Psychiatry, New York University School of Medicine, New York, New York
| | - A Hilbert
- Integrated Treatment and Research Centre (IFB) Adiposity Diseases, Leipzig University Medical Center, Leipzig, Germany.,Department of Medical Psychology and Medical Sociology, University of Leipzig, Leipzig, Germany
| | - O Sabri
- Department of Nuclear Medicine, Leipzig, Germany.,Integrated Treatment and Research Centre (IFB) Adiposity Diseases, Leipzig University Medical Center, Leipzig, Germany
| | - S Hesse
- Department of Nuclear Medicine, Leipzig, Germany.,Integrated Treatment and Research Centre (IFB) Adiposity Diseases, Leipzig University Medical Center, Leipzig, Germany
| |
Collapse
|
14
|
Löser J, Luthardt J, Rullmann M, Meyer P, Seese A, Weise D, Winkler D, Meixensberger J, Sabri O, Hesse S. EP 76. Striatal dopamine transporter availability and clinical course in Parkinson’s disease patients with deep brain stimulation of the subthalamic nucleus within one-year follow-up. Clin Neurophysiol 2016. [DOI: 10.1016/j.clinph.2016.05.258] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
15
|
Zientek F, Winter K, Müller A, Rullmann M, Luthardt J, Becker GA, Bresch A, Patt M, Sabri O, Hilbert A, Hesse S. Effortful control as a dimension of temperament is negatively associated with prefrontal serotonin transporter availability in obese and non-obese individuals. Eur J Neurosci 2016; 44:2460-2466. [PMID: 27519298 DOI: 10.1111/ejn.13362] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2016] [Revised: 07/26/2016] [Accepted: 08/02/2016] [Indexed: 11/25/2022]
Abstract
There is evidence that temperamental factors are associated with obesity; however, the biological mechanism of such association remains elusive. We aimed to investigate a possible association between serotonin transmission and regulative temperament in obese and non-obese individuals by using positron emission tomography (PET) imaging of serotonin transporters (SERT) and the Adult Temperament Questionnaire. Twenty-nine obese individuals with body mass index (BMI) ≥ 35 kg/m2 and 13 non-obese controls (BMI < 30 kg/m2 ) underwent PET with [11 C]-labeled DASB (highly selective for SERT) and self-completed the Effortful Control (EC) scale of the Adult Temperament Questionnaire-Short Form (ATQ). With the help of this questionnaire, we aimed to assess the capacity of self-regulation. Overall, for obese and non-obese individuals together, VOI-based (volume of interest) analysis showed significant negative correlations between SERT BPND and ATQ-EC AC (Activation Control) subscale in several brain regions (all r ≤ -0.47). Obese and non-obese individuals separated showed equally strong positive, but non-significant correlations. The analysis did not reveal any significant correlations of SERT availability and ATQ-EC IC (Inhibitory Control) or ATQ-EC AtC (Attentional Control) subscale within and between the two groups. The results indicate that regulative temperament - particularly the capacity to mitigate negatively toned impulses and to resist inappropriate avoidance behavior - might be associated with the prefrontal serotonergic system.
Collapse
Affiliation(s)
- Franziska Zientek
- Integrated Treatment and Research Centre (IFB) Adiposity Diseases, Leipzig University Medical Centre, Leipzig, Germany. .,Department of Nuclear Medicine, University of Leipzig, Liebigstraße 18, 04103, Leipzig, Germany.
| | - Karsten Winter
- Translational Centre for Regenerative Medicine (TRM), University of Leipzig, Leipzig, Germany
| | - Astrid Müller
- Department of Psychosomatic Medicine and Psychotherapy, Hannover Medical School, Hannover, Germany
| | - Michael Rullmann
- Integrated Treatment and Research Centre (IFB) Adiposity Diseases, Leipzig University Medical Centre, Leipzig, Germany
| | - Julia Luthardt
- Department of Nuclear Medicine, University of Leipzig, Liebigstraße 18, 04103, Leipzig, Germany
| | - Georg-Alexander Becker
- Department of Nuclear Medicine, University of Leipzig, Liebigstraße 18, 04103, Leipzig, Germany
| | - Anke Bresch
- Department of Nuclear Medicine, University of Leipzig, Liebigstraße 18, 04103, Leipzig, Germany
| | - Marianne Patt
- Department of Nuclear Medicine, University of Leipzig, Liebigstraße 18, 04103, Leipzig, Germany
| | - Osama Sabri
- Integrated Treatment and Research Centre (IFB) Adiposity Diseases, Leipzig University Medical Centre, Leipzig, Germany.,Department of Nuclear Medicine, University of Leipzig, Liebigstraße 18, 04103, Leipzig, Germany
| | - Anja Hilbert
- Integrated Treatment and Research Centre (IFB) Adiposity Diseases, Leipzig University Medical Centre, Leipzig, Germany.,Department of Medical Psychology and Medical Sociology, University of Leipzig Medical Center, Leipzig, Germany
| | - Swen Hesse
- Integrated Treatment and Research Centre (IFB) Adiposity Diseases, Leipzig University Medical Centre, Leipzig, Germany.,Department of Nuclear Medicine, University of Leipzig, Liebigstraße 18, 04103, Leipzig, Germany
| |
Collapse
|
16
|
Hankir MK, Kranz M, Gnad T, Weiner J, Wagner S, Deuther-Conrad W, Bronisch F, Steinhoff K, Luthardt J, Klöting N, Hesse S, Seibyl JP, Sabri O, Heiker JT, Blüher M, Pfeifer A, Brust P, Fenske WK. A novel thermoregulatory role for PDE10A in mouse and human adipocytes. EMBO Mol Med 2016; 8:796-812. [PMID: 27247380 PMCID: PMC4931292 DOI: 10.15252/emmm.201506085] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
Phosphodiesterase type 10A (PDE10A) is highly enriched in striatum and is under evaluation as a drug target for several psychiatric/neurodegenerative diseases. Preclinical studies implicate PDE10A in the regulation of energy homeostasis, but the mechanisms remain unclear. By utilizing small-animal PET/MRI and the novel radioligand [(18)F]-AQ28A, we found marked levels of PDE10A in interscapular brown adipose tissue (BAT) of mice. Pharmacological inactivation of PDE10A with the highly selective inhibitor MP-10 recruited BAT and potentiated thermogenesis in vivo In diet-induced obese mice, chronic administration of MP-10 caused weight loss associated with increased energy expenditure, browning of white adipose tissue, and improved insulin sensitivity. Analysis of human PET data further revealed marked levels of PDE10A in the supraclavicular region where brown/beige adipocytes are clustered in adults. Finally, the inhibition of PDE10A with MP-10 stimulated thermogenic gene expression in human brown adipocytes and induced browning of human white adipocytes. Collectively, our findings highlight a novel thermoregulatory role for PDE10A in mouse and human adipocytes and promote PDE10A inhibitors as promising candidates for the treatment of obesity and diabetes.
Collapse
Affiliation(s)
- Mohammed K Hankir
- Integrated Research and Treatment Centre for Adiposity Diseases, University Hospital University of Leipzig, Leipzig, Germany
| | - Mathias Kranz
- Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf Neuroradiopharmaceuticals, Leipzig, Germany
| | - Thorsten Gnad
- Institute of Pharmacology and Toxicology, University Hospital University of Bonn, Bonn, Germany
| | - Juliane Weiner
- Integrated Research and Treatment Centre for Adiposity Diseases, University Hospital University of Leipzig, Leipzig, Germany
| | - Sally Wagner
- Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf Neuroradiopharmaceuticals, Leipzig, Germany
| | - Winnie Deuther-Conrad
- Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf Neuroradiopharmaceuticals, Leipzig, Germany
| | - Felix Bronisch
- Integrated Research and Treatment Centre for Adiposity Diseases, University Hospital University of Leipzig, Leipzig, Germany
| | - Karen Steinhoff
- Department of Nuclear Medicine, University Hospital University of Leipzig, Leipzig, Germany
| | - Julia Luthardt
- Department of Nuclear Medicine, University Hospital University of Leipzig, Leipzig, Germany
| | - Nora Klöting
- Integrated Research and Treatment Centre for Adiposity Diseases, University Hospital University of Leipzig, Leipzig, Germany
| | - Swen Hesse
- Integrated Research and Treatment Centre for Adiposity Diseases, University Hospital University of Leipzig, Leipzig, Germany Department of Nuclear Medicine, University Hospital University of Leipzig, Leipzig, Germany
| | | | - Osama Sabri
- Integrated Research and Treatment Centre for Adiposity Diseases, University Hospital University of Leipzig, Leipzig, Germany Department of Nuclear Medicine, University Hospital University of Leipzig, Leipzig, Germany
| | - John T Heiker
- Integrated Research and Treatment Centre for Adiposity Diseases, University Hospital University of Leipzig, Leipzig, Germany
| | - Matthias Blüher
- Integrated Research and Treatment Centre for Adiposity Diseases, University Hospital University of Leipzig, Leipzig, Germany
| | - Alexander Pfeifer
- Institute of Pharmacology and Toxicology, University Hospital University of Bonn, Bonn, Germany
| | - Peter Brust
- Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf Neuroradiopharmaceuticals, Leipzig, Germany
| | - Wiebke K Fenske
- Integrated Research and Treatment Centre for Adiposity Diseases, University Hospital University of Leipzig, Leipzig, Germany
| |
Collapse
|
17
|
Bresch A, Rullmann M, Luthardt J, Arelin K, Becker GA, Patt M, Lobsien D, Baldofski S, Drabe M, Zeisig V, Regenthal R, Blüher M, Hilbert A, Sabri O, Hesse S. In-vivo serotonin transporter availability and somatization in healthy subjects. Personality and Individual Differences 2016. [DOI: 10.1016/j.paid.2016.01.042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
18
|
Melasch J, Rullmann M, Hilbert A, Luthardt J, Becker GA, Patt M, Stumvoll M, Blüher M, Villringer A, Arelin K, Meyer PM, Bresch A, Sabri O, Hesse S, Pleger B. Sex differences in serotonin-hypothalamic connections underpin a diminished sense of emotional well-being with increasing body weight. Int J Obes (Lond) 2016; 40:1268-77. [PMID: 27102051 DOI: 10.1038/ijo.2016.63] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/04/2015] [Revised: 01/11/2016] [Accepted: 01/28/2016] [Indexed: 12/27/2022]
Abstract
BACKGROUND/OBJECTIVES The neurobiological mechanisms linking obesity to emotional distress related to weight remain largely unknown. PARTICIPANTS/METHODS Here we combined positron emission tomography, using the serotonin transporter (5-HTT) radiotracer [(11)C]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile, with functional connectivity magnetic resonance imaging, the Beck Depression Inventory (BDI-II) and the Impact of Weight on Quality of Life-Lite questionnaire (IWQOL-Lite) to investigate the role of central serotonin in the severity of depression (BDI-II), as well as in the loss of emotional well-being with body weight (IWQOL-Lite). RESULTS In a group of lean to morbidly obese individuals (n=28), we found sex differences in the 5-HTT availability-related connectivity of the hypothalamus. Males (n=11) presented a strengthened connectivity to the lateral orbitofrontal cortex, whereas in females (n=17) we found strengethened projections to the ventral striatum. Both regions are known as reward regions involved in mediating the emotional response to food. Their resting-state activity correlated positively to the body mass index (BMI) and IWQOL-Lite scores, suggesting that each region in both sexes also underpins a diminished sense of emotional well-being with body weight. Contrarily to males, we found that in females also the BDI-II positively correlated with the BMI and by trend with the activity in ventral striatum, suggesting that in females an increased body weight may convey to other mood dimensions than those weight-related ones included in the IWQOL-Lite. CONCLUSIONS This study suggests sex differences in serotonin-hypothalamic connections to brain regions of the reward circuitry underpinning a diminished sense of emotional well-being with an increasing body weight.
Collapse
Affiliation(s)
- J Melasch
- IFB Adiposity Diseases, University Medical Centre, Leipzig, Germany.,Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany
| | - M Rullmann
- IFB Adiposity Diseases, University Medical Centre, Leipzig, Germany.,Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany
| | - A Hilbert
- IFB Adiposity Diseases, University Medical Centre, Leipzig, Germany
| | - J Luthardt
- Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany
| | - G A Becker
- Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany
| | - M Patt
- Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany
| | - M Stumvoll
- IFB Adiposity Diseases, University Medical Centre, Leipzig, Germany.,Medical Department III, University Hospital Leipzig, Leipzig, Germany
| | - M Blüher
- IFB Adiposity Diseases, University Medical Centre, Leipzig, Germany.,Medical Department III, University Hospital Leipzig, Leipzig, Germany
| | - A Villringer
- IFB Adiposity Diseases, University Medical Centre, Leipzig, Germany.,Department of Neurology, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany.,Clinic for Cognitive Neurology, University Hospital Leipzig, Leipzig, Germany
| | - K Arelin
- IFB Adiposity Diseases, University Medical Centre, Leipzig, Germany.,Department of Neurology, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany.,Clinic for Cognitive Neurology, University Hospital Leipzig, Leipzig, Germany
| | - P M Meyer
- Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany
| | - A Bresch
- Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany
| | - O Sabri
- IFB Adiposity Diseases, University Medical Centre, Leipzig, Germany.,Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany
| | - S Hesse
- IFB Adiposity Diseases, University Medical Centre, Leipzig, Germany.,Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany
| | - B Pleger
- IFB Adiposity Diseases, University Medical Centre, Leipzig, Germany.,Department of Neurology, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany.,Clinic for Cognitive Neurology, University Hospital Leipzig, Leipzig, Germany.,BG University Clinic Bergmannsheil, Department of Neurology, Ruhr University Bochum, Bochum, Germany
| |
Collapse
|
19
|
Hinderberger P, Rullmann M, Drabe M, Luthardt J, Becker GA, Blüher M, Regenthal R, Sabri O, Hesse S. The effect of serum BDNF levels on central serotonin transporter availability in obese versus non-obese adults: A [(11)C]DASB positron emission tomography study. Neuropharmacology 2016; 110:530-536. [PMID: 27108933 DOI: 10.1016/j.neuropharm.2016.04.030] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2015] [Revised: 02/26/2016] [Accepted: 04/20/2016] [Indexed: 01/09/2023]
Abstract
BACKGROUND Serotonin (5-HT) and its neurotrophic support system, specifically brain-derived neurotrophic factor (BDNF), are thought to modulate energy homeostasis and susceptibility to obesity. Moreover, a polymorphism (5-HTTLPR) in the serotonin reuptake transporter (5-HTT) gene impairs its transcription, thereby altering serotonergic tone and potentially contributing to such susceptibility. This study aims to investigate the effect of BDNF, biallelic 5-HTTLPR, and central in-vivo 5-HTT availability in highly obese versus non-obese subjects using positron emission tomography (PET) and 5-HTT selective [(11)C]DASB. METHODS Thirty-eight subjects, 24 obese, otherwise mentally and physically healthy, and 14 non-obese healthy controls were included in this study. Parametric images of binding potential were generated from PET data. Central 5-HTT availability, 5-HTTLPR genotype, and serum BDNF concentrations were analyzed, first in a volume of interest, then in a voxel-wise manner. RESULTS Overall, our results showed an absence of a linear correlation between BDNF, in-vivo central 5-HTT availability, and body mass index (BMI). 5-HTTLPR genotyping revealed BDNF and hippocampal 5-HTT availability to be negatively correlated (r = -0.57, p = 0.007) in long allelic homozygotes. However, obese subjects exhibited opposing effects of BDNF levels on 5-HTT availability in the nucleus accumbens (NAcc) relative to our non-obese controls. CONCLUSIONS Our data did not confirm an overall correlation between serum BDNF, in-vivo central 5-HTT availability, 5-HTTLPR, and BMI. However, there is evidence that serotonergic tone linked to BDNF, specifically in the NAcc, is involved in the pathophysiology of obesity, although this needs further exploration over a wide range of reward-related eating behaviors.
Collapse
Affiliation(s)
- Philipp Hinderberger
- Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany; Integrated Research and Treatment Center (IFB) Adiposity Diseases, University of Leipzig, Leipzig, Germany
| | - Michael Rullmann
- Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany; Integrated Research and Treatment Center (IFB) Adiposity Diseases, University of Leipzig, Leipzig, Germany
| | - Mandy Drabe
- Integrated Research and Treatment Center (IFB) Adiposity Diseases, University of Leipzig, Leipzig, Germany
| | - Julia Luthardt
- Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany
| | | | - Matthias Blüher
- Integrated Research and Treatment Center (IFB) Adiposity Diseases, University of Leipzig, Leipzig, Germany
| | - Ralf Regenthal
- Division of Clinical Pharmacology, Rudolf-Boehm-Institute of Pharmacology and Toxicology, University of Leipzig, Leipzig, Germany
| | - Osama Sabri
- Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany; Integrated Research and Treatment Center (IFB) Adiposity Diseases, University of Leipzig, Leipzig, Germany
| | - Swen Hesse
- Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany; Integrated Research and Treatment Center (IFB) Adiposity Diseases, University of Leipzig, Leipzig, Germany.
| |
Collapse
|
20
|
Tuszynski T, Rullmann M, Luthardt J, Butzke D, Tiepolt S, Gertz HJ, Hesse S, Seese A, Lobsien D, Sabri O, Barthel H. Evaluation of software tools for automated identification of neuroanatomical structures in quantitative β-amyloid PET imaging to diagnose Alzheimer’s disease. Eur J Nucl Med Mol Imaging 2016; 43:1077-87. [DOI: 10.1007/s00259-015-3300-6] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2015] [Accepted: 12/22/2015] [Indexed: 11/25/2022]
|
21
|
Hesse S, Rullmann M, Luthardt J, Winter K, Hankir MK, Becker GA, Zientek F, Reissig G, Regenthal R, Drabe M, Schinke C, Bresch A, Arelin K, Lobsien D, Patt M, Meyer PM, Fasshauer M, Fenske WK, Blüher M, Stumvoll M, Sabri O. Central serotonin transporter availability in highly obese individuals compared with non-obese controls: A [(11)C] DASB positron emission tomography study. Eur J Nucl Med Mol Imaging 2015; 43:1096-104. [PMID: 26577939 DOI: 10.1007/s00259-015-3243-y] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2015] [Accepted: 10/27/2015] [Indexed: 01/11/2023]
Abstract
PURPOSE The role of the central serotonin (5-hydroxytryptamine, 5-HT) system in feeding has been extensively studied in animals with the 5-HT family of transporters (5-HTT) being identified as key molecules in the regulation of satiety and body weight. Aberrant 5-HT transmission has been implicated in the pathogenesis of human obesity by in vivo positron emission tomography (PET) and single-photon emission computed tomography (SPECT) imaging techniques. However, results obtained thus far from studies of central 5-HTT availability have been inconsistent, which is thought to be brought about mainly by the low number of individuals with a high body mass index (BMI) previously used. The aim of this study was therefore to assess 5-HTT availability in the brains of highly obese otherwise healthy individuals compared with non-obese healthy controls. METHODS We performed PET using the 5-HTT selective radiotracer [(11)C] DASB on 30 highly obese (BMI range between 35 and 55 kg/m(2)) and 15 age- and sex-matched non-obese volunteers (BMI range between 19 and 27 kg/m(2)) in a cross-sectional study design. The 5-HTT binding potential (BPND) was used as the outcome parameter. RESULTS On a group level, there was no significant difference in 5-HTT BPND in various cortical and subcortical regions in individuals with the highest BMI compared with non-obese controls, while statistical models showed minor effects of age, sex, and the degree of depression on 5-HTT BPND. CONCLUSION The overall finding of a lack of significantly altered 5-HTT availability together with its high variance in obese individuals justifies the investigation of individual behavioral responses to external and internal cues which may further define distinct phenotypes and subgroups in human obesity.
Collapse
Affiliation(s)
- Swen Hesse
- Department of Nuclear Medicine, University of Leipzig, Liebigstraße 18, 04103, Leipzig, Germany.
- Integrated Research and Treatment Centre Adiposity Diseases Leipzig, Leipzig, Germany.
| | - Michael Rullmann
- Department of Nuclear Medicine, University of Leipzig, Liebigstraße 18, 04103, Leipzig, Germany
- Integrated Research and Treatment Centre Adiposity Diseases Leipzig, Leipzig, Germany
- Max Planck Institute for Human Cognitive and Brain Sciences Leipzig, Leipzig, Germany
| | - Julia Luthardt
- Department of Nuclear Medicine, University of Leipzig, Liebigstraße 18, 04103, Leipzig, Germany
| | - Karsten Winter
- Centre for Translational Regenerative Medicine, University of Leipzig, Leipzig, Germany
- Institute for Medical Informatics, Statistics, and Epidemiology, University of Leipzig, Leipzig, Germany
| | - Mohammed K Hankir
- Integrated Research and Treatment Centre Adiposity Diseases Leipzig, Leipzig, Germany
| | - Georg-Alexander Becker
- Department of Nuclear Medicine, University of Leipzig, Liebigstraße 18, 04103, Leipzig, Germany
| | - Franziska Zientek
- Integrated Research and Treatment Centre Adiposity Diseases Leipzig, Leipzig, Germany
| | - Georg Reissig
- Integrated Research and Treatment Centre Adiposity Diseases Leipzig, Leipzig, Germany
| | - Ralf Regenthal
- Division of Clinical Pharmacology, Rudolf Boehm Institute of Pharmacology and Toxicology, University of Leipzig, Leipzig, Germany
| | - Mandy Drabe
- Integrated Research and Treatment Centre Adiposity Diseases Leipzig, Leipzig, Germany
| | | | - Anke Bresch
- Department of Nuclear Medicine, University of Leipzig, Liebigstraße 18, 04103, Leipzig, Germany
| | - Katrin Arelin
- Max Planck Institute for Human Cognitive and Brain Sciences Leipzig, Leipzig, Germany
- Day Clinic for Cognitive Neurology, University of Leipzig, Leipzig, Germany
| | - Donald Lobsien
- Department of Neuroradiology, University of Leipzig, Leipzig, Germany
| | - Marianne Patt
- Department of Nuclear Medicine, University of Leipzig, Liebigstraße 18, 04103, Leipzig, Germany
| | - Philipp M Meyer
- Department of Nuclear Medicine, University of Leipzig, Liebigstraße 18, 04103, Leipzig, Germany
| | - Mathias Fasshauer
- Integrated Research and Treatment Centre Adiposity Diseases Leipzig, Leipzig, Germany
- Medical Department III, University of Leipzig, Leipzig, Germany
| | - Wiebke K Fenske
- Integrated Research and Treatment Centre Adiposity Diseases Leipzig, Leipzig, Germany
- Medical Department III, University of Leipzig, Leipzig, Germany
| | - Matthias Blüher
- Medical Department III, University of Leipzig, Leipzig, Germany
- Collaborative Research Centre 1052 Obesity Mechanisms, University of Leipzig, Leipzig, Germany
| | - Michael Stumvoll
- Integrated Research and Treatment Centre Adiposity Diseases Leipzig, Leipzig, Germany
- Medical Department III, University of Leipzig, Leipzig, Germany
| | - Osama Sabri
- Department of Nuclear Medicine, University of Leipzig, Liebigstraße 18, 04103, Leipzig, Germany
- Integrated Research and Treatment Centre Adiposity Diseases Leipzig, Leipzig, Germany
| |
Collapse
|
22
|
Rullmann M, Dukart J, Hoffmann KT, Luthardt J, Tiepolt S, Patt M, Gertz HJ, Schroeter ML, Seibyl J, Schulz-Schaeffer WJ, Sabri O, Barthel H. Partial-Volume Effect Correction Improves Quantitative Analysis of 18F-Florbetaben β-Amyloid PET Scans. J Nucl Med 2015; 57:198-203. [PMID: 26541776 DOI: 10.2967/jnumed.115.161893] [Citation(s) in RCA: 54] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2015] [Accepted: 10/21/2015] [Indexed: 11/16/2022] Open
Abstract
UNLABELLED Neocortical atrophy reduces PET signal intensity, potentially affecting the diagnostic efficacy of β-amyloid (Aβ) brain PET imaging. This study investigated whether partial-volume effect correction (PVEC), adjusting for this atrophy bias, improves the accuracy of (18)F-florbetaben Aβ PET. METHODS We analyzed (18)F-florbetaben PET and MRI data obtained from 3 cohorts. The first was 10 patients with probable Alzheimer disease (AD) and 10 age-matched healthy controls (HCs), the second was 31 subjects who underwent in vivo imaging and postmortem histopathology for Aβ plaques, and the third was 5 subjects who underwent PET and MRI at baseline and 1 y later. The imaging data were coregistered and segmented. PVEC was performed using the voxel-based modified Müller-Gärtner method (PVELab, SPM8). From the PET data, regional and composite SUV ratios (SUVRs) with and without PVEC were obtained. In the MRI data, mesial temporal lobe atrophy was determined by the Scheltens mesial temporal atrophy scale and gray matter volumes by voxel-based morphometry. RESULTS In cohort 1, PVEC increased the effect on AD-versus-HC discrimination from a Cohen d value of 1.68 to 2.0 for composite SUVRs and from 0.04 to 1.04 for mesial temporal cortex SUVRs. The PVEC-related increase in mesial temporal cortex SUVR correlated with the Scheltens score (r = 0.84, P < 0.001), and that of composite SUVR correlated with the composite gray matter volume (r = -0.75, P < 0.001). In cohort 2, PVEC increased the correlation coefficient between mesial temporal cortex SUVR and histopathology score for Aβ plaque load from 0.28 (P = 0.09) to 0.37 (P = 0.03). In cohort 3, PVEC did not affect the composite SUVR dynamics over time for the Aβ-negative subject. This finding was in contrast to the 4 Aβ-positive subjects, in 2 of whom PVEC changed the composite SUVR dynamics. CONCLUSION The influence of PVEC on (18)F-florbetaben PET data is associated with the degree of brain atrophy. Thus, PVEC increases the ability of (18)F-florbetaben PET to discriminate between AD patients and HCs, to detect Aβ plaques in the atrophic mesial temporal cortex, and potentially to evaluate changes in brain Aβ load over time. As such, the use of PVEC should be considered for quantitative (18)F-florbetaben PET scans, especially in assessing patients with brain atrophy.
Collapse
Affiliation(s)
- Michael Rullmann
- Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany
| | - Juergen Dukart
- LREN, Département des Neurosciences Cliniques, CHUV, Université de Lausanne, Lausanne, Switzerland Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany
| | | | - Julia Luthardt
- Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany
| | - Solveig Tiepolt
- Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany
| | - Marianne Patt
- Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany
| | | | - Matthias L Schroeter
- Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany Clinic for Cognitive Neurology, University Hospital Leipzig, Leipzig, Germany
| | - John Seibyl
- Molecular NeuroImaging, L.L.C., New Haven, Connecticut; and
| | | | - Osama Sabri
- Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany
| | - Henryk Barthel
- Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany
| |
Collapse
|
23
|
Melasch J, Rullmann M, Hilbert A, Luthardt J, Becker GA, Patt M, Villringer A, Arelin K, Meyer PM, Lobsien D, Ding YS, Müller K, Sabri O, Hesse S, Pleger B. The central nervous norepinephrine network links a diminished sense of emotional well-being to an increased body weight. Int J Obes (Lond) 2015; 40:779-87. [PMID: 26620766 DOI: 10.1038/ijo.2015.216] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/29/2015] [Revised: 09/25/2015] [Accepted: 09/28/2015] [Indexed: 01/04/2023]
Abstract
OBJECTIVES The neurobiological mechanisms linking obesity to emotional distress remain largely undiscovered. METHODS In this pilot study, we combined positron emission tomography, using the norepinephrine transporter (NET) tracer [(11)C]-O-methylreboxetine, with functional connectivity magnetic resonance imaging, the Beck depression inventory (BDI), and the impact of weight on quality of life-Lite questionnaire (IWQOL-Lite), to investigate the role of norepinephrine in the severity of depression (BDI), as well as in the loss of emotional well-being with body weight (IWQOL-Lite). RESULTS In a small group of lean-to-morbidly obese individuals (n=20), we show that an increased body mass index (BMI) is related to a lowered NET availability within the hypothalamus, known as the brain's homeostatic control site. The hypothalamus displayed a strengthened connectivity in relation to the individual hypothalamic NET availability to the anterior insula/frontal operculum, as well as the medial orbitofrontal cortex, assumed to host the primary and secondary gustatory cortex, respectively (n=19). The resting-state activity in these two regions was correlated positively to the BMI and IWQOL-Lite scores, but not to the BDI, suggesting that the higher the resting-state activity in these regions, and hence the higher the BMI, the stronger the negative impact of the body weight on the individual's emotional well-being was. CONCLUSIONS This pilot study suggests that the loss in emotional well-being with weight is embedded within the central norepinephrine network.
Collapse
Affiliation(s)
- J Melasch
- IFB Adiposity Diseases, University Medical Centre, Leipzig, Germany.,Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany
| | - M Rullmann
- IFB Adiposity Diseases, University Medical Centre, Leipzig, Germany.,Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany
| | - A Hilbert
- IFB Adiposity Diseases, University Medical Centre, Leipzig, Germany
| | - J Luthardt
- Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany
| | - G A Becker
- Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany
| | - M Patt
- Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany
| | - A Villringer
- IFB Adiposity Diseases, University Medical Centre, Leipzig, Germany.,Department of Neurology, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany.,Clinic for Cognitive Neurology, University Hospital Leipzig, Leipzig, Germany
| | - K Arelin
- Department of Neurology, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany.,Clinic for Cognitive Neurology, University Hospital Leipzig, Leipzig, Germany
| | - P M Meyer
- Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany
| | - D Lobsien
- Department of Radiology, University Hospital Leipzig, Leipzig, Germany
| | - Y-S Ding
- Department of Radiology, Psychiatry, and Chemistry, New York University School of Medicine, New York, USA
| | - K Müller
- Department of Neurology, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany
| | - O Sabri
- IFB Adiposity Diseases, University Medical Centre, Leipzig, Germany.,Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany
| | - S Hesse
- IFB Adiposity Diseases, University Medical Centre, Leipzig, Germany.,Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany
| | - B Pleger
- IFB Adiposity Diseases, University Medical Centre, Leipzig, Germany.,Department of Neurology, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany.,Clinic for Cognitive Neurology, University Hospital Leipzig, Leipzig, Germany
| |
Collapse
|
24
|
Sabri O, Becker GA, Meyer PM, Hesse S, Wilke S, Graef S, Patt M, Luthardt J, Wagenknecht G, Hoepping A, Smits R, Franke A, Sattler B, Habermann B, Neuhaus P, Fischer S, Tiepolt S, Deuther-Conrad W, Barthel H, Schönknecht P, Brust P. First-in-human PET quantification study of cerebral α4β2* nicotinic acetylcholine receptors using the novel specific radioligand (−)-[ 18 F]Flubatine. Neuroimage 2015; 118:199-208. [DOI: 10.1016/j.neuroimage.2015.05.065] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2014] [Revised: 05/15/2015] [Accepted: 05/24/2015] [Indexed: 10/23/2022] Open
|
25
|
Hesse S, Moeller F, Petroff D, Lobsien D, Luthardt J, Regenthal R, Becker GA, Patt M, Thomae E, Seese A, Meyer PM, Bergh FT, Sabri O. Altered serotonin transporter availability in patients with multiple sclerosis. Eur J Nucl Med Mol Imaging 2014; 41:827-35. [DOI: 10.1007/s00259-013-2636-z] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2013] [Accepted: 11/06/2013] [Indexed: 01/20/2023]
|
26
|
Becker GA, Ichise M, Barthel H, Luthardt J, Patt M, Seese A, Schultze-Mosgau M, Rohde B, Gertz HJ, Reininger C, Sabri O. PET quantification of 18F-florbetaben binding to β-amyloid deposits in human brains. J Nucl Med 2013; 54:723-31. [PMID: 23471310 DOI: 10.2967/jnumed.112.107185] [Citation(s) in RCA: 89] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
UNLABELLED (18)F-florbetaben is a novel (18)F-labeled tracer for PET imaging of β-amyloid deposits in the human brain. We evaluated the kinetic model-based approaches to the quantification of β-amyloid binding in the brain from dynamic PET data. The validity of the practically useful tissue ratio was also evaluated against the model-based parameters. METHODS (18)F-florbetaben PET imaging was performed with concurrent multiple arterial sampling after tracer injection (300 MBq) in 10 Alzheimer disease (AD) patients and 10 age-matched healthy controls. Regional brain-tissue time-activity curves for 90 min were analyzed by a 1-tissue-compartment model and a 2-tissue-compartment model (2TCM) with metabolite-corrected plasma data estimating the specific distribution volume (VS) and distribution volume ratio (DVR [2TCM]) and a multilinear reference tissue model estimating DVR (DVR [MRTM]) using the cerebellar cortex as the reference tissue. Target-to-reference tissue standardized uptake value ratios (SUVRs) at 70-90 min were also calculated. RESULTS All brain regions required 2TCM to describe the time-activity curves. All β-amyloid binding parameters in the cerebral cortex (VS, DVR [2TCM], DVR [MRTM], and SUVR) were significantly increased in AD patients (P < 0.05), and there were significant linear correlations among these parameters (r(2) > 0.83). Effect sizes in group discrimination between 8 β-amyloid-positive AD scans and 9 β-amyloid-negative healthy control scans for all binding parameters were excellent, being largest for DVR (2TCM) (4.22) and smallest for VS (3.25) and intermediate and the same for DVR (MRTM) and SUVR (4.03). CONCLUSION These results suggest that compartment kinetic model-based quantification of β-amyloid binding from (18)F-florbetaben PET data is feasible and that all β-amyloid binding parameters including SUVR are excellent in discriminating between β-amyloid-positive and -negative scans.
Collapse
Affiliation(s)
- Georg A Becker
- Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Hesse S, Brust P, Mäding P, Becker GA, Patt M, Seese A, Sorger D, Zessin J, Meyer PM, Lobsien D, Laudi S, Habermann B, Füchtner F, Luthardt J, Bresch A, Steinbach J, Sabri O. Imaging of the brain serotonin transporters (SERT) with 18F-labelled fluoromethyl-McN5652 and PET in humans. Eur J Nucl Med Mol Imaging 2012; 39:1001-11. [PMID: 22349718 DOI: 10.1007/s00259-012-2078-z] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2011] [Accepted: 01/26/2012] [Indexed: 11/28/2022]
Abstract
PURPOSE [(11)C]DASB is currently the most frequently used highly selective radiotracer for visualization and quantification of central SERT. Its use, however, is hampered by the short half-life of (11)C, the moderate cortical test-retest reliability, and the lack of quantifying endogenous serotonin. Labelling with (18)F allows in principle longer acquisition times for kinetic analysis in brain tissue and may provide higher sensitivity. The aim of our study was to firstly use the new highly SERT-selective (18)F-labelled fluoromethyl analogue of (+)-McN5652 ((+)-[(18)F]FMe-McN5652) in humans and to evaluate its potential for SERT quantification. METHODS The PET data from five healthy volunteers (three men, two women, age 39 ± 10 years) coregistered with individual MRI scans were semiquantitatively assessed by volume-of-interest analysis using the software package PMOD. Rate constants and total distribution volumes (V (T)) were calculated using a two-tissue compartment model and arterial input function measurements were corrected for metabolite/plasma data. Standardized uptake region-to-cerebellum ratios as a measure of specific radiotracer accumulation were compared with those of a [(11)C]DASB PET dataset from 21 healthy subjects (10 men, 11 women, age 38 ± 8 years). RESULTS The two-tissue compartment model provided adequate fits to the data. Estimates of total distribution volume (V (T)) demonstrated good identifiability based on the coefficients of variation (COV) for the volumes of interest in SERT-rich and cortical areas (COV V (T) <10%). Compared with [(11)C]DASB PET, there was a tendency to lower mean uptake values in (+)-[(18)F]FMe-McN5652 PET; however, the standard deviation was also somewhat lower. Altogether, cerebral (+)-[(18)F]FMe-McN5652 uptake corresponded well with the known SERT distribution in humans. CONCLUSION The results showed that (+)-[(18)F]FMe-McN5652 is also suitable for in vivo quantification of SERT with PET. Because of the long half-life of (18)F, the widespread use within a satellite concept seems feasible.
Collapse
Affiliation(s)
- Swen Hesse
- Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Barthel H, Luthardt J, Becker G, Patt M, Hammerstein E, Hartwig K, Eggers B, Sattler B, Schildan A, Hesse S, Meyer PM, Wolf H, Zimmermann T, Reischl J, Rohde B, Gertz HJ, Reininger C, Sabri O. Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer’s disease and healthy controls. Eur J Nucl Med Mol Imaging 2011; 38:1702-14. [DOI: 10.1007/s00259-011-1821-1] [Citation(s) in RCA: 70] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2010] [Accepted: 04/06/2011] [Indexed: 10/18/2022]
|
29
|
Guenther T, Schönknecht P, Becker G, Olbrich S, Sander C, Hesse S, Meyer PM, Luthardt J, Hegerl U, Sabri O. Impact of EEG-vigilance on brain glucose uptake measured with [18F]FDG and PET in patients with depressive episode or mild cognitive impairment. Neuroimage 2011; 56:93-101. [DOI: 10.1016/j.neuroimage.2011.01.059] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2010] [Revised: 01/04/2011] [Accepted: 01/20/2011] [Indexed: 11/30/2022] Open
|
30
|
Kendziorra K, Wolf H, Meyer PM, Barthel H, Hesse S, Becker GA, Luthardt J, Schildan A, Patt M, Sorger D, Seese A, Gertz HJ, Sabri O. Decreased cerebral α4β2* nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer's disease assessed with positron emission tomography. Eur J Nucl Med Mol Imaging 2010; 38:515-25. [PMID: 21069319 DOI: 10.1007/s00259-010-1644-5] [Citation(s) in RCA: 96] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2010] [Accepted: 10/04/2010] [Indexed: 01/14/2023]
Abstract
PURPOSE Postmortem studies indicate a loss of nicotinic acetylcholine receptor (nAChRs) in Alzheimer's disease (AD). In order to establish whether these changes in the cholinergic system occur at an early stage of AD, we carried out positron emission tomography (PET) with a specific radioligand for the α4β2* nicotinic acetylcholine receptor (α4β2* nAChR) in patients with mild to moderate AD and in patients with amnestic mild cognitive impairment (MCI), who have a high risk to progress to AD. METHODS Nine patients with moderate AD, eight patients with MCI and seven age-matched healthy controls underwent 2-[(18)F]fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-[(18)F]FA-85380) PET. After coregistration with individual magnetic resonance imaging the binding potential (BP(ND)) of 2-[(18)F]FA-85380 was calculated using either the corpus callosum or the cerebellum as reference regions. PET data were analysed by region of interest analysis and by voxel-based analysis. RESULTS Both patients with AD and MCI showed a significant reduction in 2-[(18)F]FA-85380 BP(ND) in typical AD-affected brain regions. Thereby, the corpus callosum was identified as the most suitable reference region. The 2-[(18)F]FA-85380 BP(ND) correlated with the severity of cognitive impairment. Only MCI patients that converted to AD in the later course (n = 5) had a reduction in 2-[(18)F]FA-85380 BP(ND). CONCLUSION 2-[(18)F]FA-85380 PET appears to be a sensitive and feasible tool for the detection of a reduction in α4β2* nAChRs which seems to be an early event in AD. In addition, 2-[(18)F]FA-85380 PET might give prognostic information about a conversion from MCI to AD.
Collapse
Affiliation(s)
- Kai Kendziorra
- Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Ichise M, Becker G, Henryk B, Patt M, Luthardt J, Gertz H, Schultze-Mosgau M, Rohde B, Reininger C, Sabri O. Compartment-model based quantification of beta-amyloid binding with Florbetaben PET in Alzheimer's disease and control subjects. Neuroimage 2010. [DOI: 10.1016/j.neuroimage.2010.04.152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
32
|
Becker G, Ichise M, Barthel H, Luthardt J, Patt M, Schultze-Mosgau M, Reininger C, Hegerl U, Gertz HJ, Sabri O. Kinetic modeling of florbetaben binding to beta-amyloid in human brains using one and two input functions. Neuroimage 2010. [DOI: 10.1016/j.neuroimage.2010.04.113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
33
|
Barthel H, Senda M, Luthardt J, Strick A, Yamane T, Patt M, Sattler B, Seibyl J, Zimmermann T, Rohde B, Reininger C, Gertz HJ, Sabri O. P2‐402: Influence of ethnic group, age, gender, and tracer mass dose on florbetaben β‐amyloid brain PET results in elderly normal controls. Alzheimers Dement 2010. [DOI: 10.1016/j.jalz.2010.05.1455] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
| | - Michio Senda
- Institute of Biomedical Research and InnovationKobe Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Sabri O, Barthel H, Becker G, Luthardt J, Patt M, Hammerstein E, Hartwig K, Schildan A, Hesse S, Meyer P, Seese A, Reischl J, Hegerl U, Reininger C, Rohde B, Gertz H. P2‐002: [
18
F]BAY 94‐9172 PET ‐ Towards in vivo quantification of brain β‐amyloid plaque load in Alzheimer disease. Alzheimers Dement 2009. [DOI: 10.1016/j.jalz.2009.04.311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Osama Sabri
- Department of Nuclear MedicineUniversity of LeipzigLeipzigGermany
| | - Henryk Barthel
- Department of Nuclear MedicineUniversity of LeipzigLeipzigGermany
| | - Georg Becker
- Department of Nuclear MedicineUniversity of LeipzigLeipzigGermany
| | - Julia Luthardt
- Department of Nuclear MedicineUniversity of LeipzigLeipzigGermany
| | - Marianne Patt
- Department of Nuclear MedicineUniversity of LeipzigLeipzigGermany
| | | | | | - Andreas Schildan
- Department of Nuclear MedicineUniversity of LeipzigLeipzigGermany
| | - Swen Hesse
- Department of Nuclear MedicineUniversity of LeipzigLeipzigGermany
| | - Phillip Meyer
- Department of Nuclear MedicineUniversity of LeipzigLeipzigGermany
| | - Anita Seese
- Department of Nuclear MedicineUniversity of LeipzigLeipzigGermany
| | | | - Ulrich Hegerl
- Department of PsychiatryUniversity of LeipzigLeipzigGermany
| | | | | | | |
Collapse
|
35
|
Sabri O, Barthel H, Patt M, Hammerstein E, Becker G, Eggers B, Luthardt J, Schildan A, Hesse S, Kendziorra K, Hartwig K, Lindemann S, Holl G, Reininger C, Hegerl U, Gertz HJ. P1‐285: First results toward
in vivo
quantification of cerebral β‐amyloid plaque load in Alzheimer's disease by means of BAY 94–9172‐PET. Alzheimers Dement 2008. [DOI: 10.1016/j.jalz.2008.05.875] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Affiliation(s)
- Osama Sabri
- Department of Nuclear MedicineUniversity of LeipzigLeipzigGermany
| | - Henryk Barthel
- Department of Nuclear MedicineUniversity of LeipzigLeipzigGermany
| | - Marianne Patt
- Department of Nuclear MedicineUniversity of LeipzigLeipzigGermany
| | | | - Georg Becker
- Department of Nuclear MedicineUniversity of LeipzigLeipzigGermany
| | - Birk Eggers
- Arzneimittelforschung Leipzig Ltd.LeipzigGermany
| | - Julia Luthardt
- Department of Nuclear MedicineUniversity of LeipzigLeipzigGermany
| | - Andreas Schildan
- Department of Nuclear MedicineUniversity of LeipzigLeipzigGermany
| | - Swen Hesse
- Department of Nuclear MedicineUniversity of LeipzigLeipzigGermany
| | - Kai Kendziorra
- Department of Nuclear MedicineUniversity of LeipzigLeipzigGermany
| | | | | | | | | | - Ulrich Hegerl
- Department of PsychiatryUniversity of LeipzigLeipzigGermany
| | | |
Collapse
|
36
|
Hesse S, Strecker K, Winkler D, Luthardt J, Scherfler C, Reupert A, Oehlwein C, Barthel H, Schneider JP, Wegner F, Meyer P, Meixensberger J, Sabri O, Schwarz J. Effects of subthalamic nucleus stimulation on striatal dopaminergic transmission in patients with Parkinson’s disease within one-year follow-up. J Neurol 2008; 255:1059-66. [PMID: 18446306 DOI: 10.1007/s00415-008-0849-z] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2007] [Revised: 11/30/2007] [Accepted: 12/18/2007] [Indexed: 11/25/2022]
Affiliation(s)
- Swen Hesse
- Dept. of Nuclear Medicine, University of Leipzig, Stephanstrasse 11, 04103 Leipzig, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Luthardt J, Borvendeg SJ, Sperlagh B, Poelchen W, Wirkner K, Illes P. P2Y(1) receptor activation inhibits NMDA receptor-channels in layer V pyramidal neurons of the rat prefrontal and parietal cortex. Neurochem Int 2003; 42:161-72. [PMID: 12421596 DOI: 10.1016/s0197-0186(02)00069-4] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
In the 1st part of this study, monosynaptic excitatory postsynaptic potentials (EPSPs) in layer V of the rat prefrontal cortex (PFC) were evoked by electrical stimulation of layer I. Recordings with intracellular sharp, microelectrodes showed a concentration-dependent inhibition of the EPSP by adenosine 5'-O-(2-thiodiphosphate) (ADP-beta-S). Pyridoxal-phosphate-6-azophenyl-2',4'-disulphonic acid (PPADS), when given alone depressed the EPSP and in addition antagonized the effect of ADP-beta-S. Exclusion of the N-methyl-D-aspartate (NMDA) component of the EPSP by D(.)-amino-5-phosphonopentanoic acid (AP-5) abolished the ADP-beta-S-induced depression. The pressure-application of both NMDA and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) caused reproducible depolarizations. ADP-beta-S inhibited the effect of NMDA, but did not alter that of AMPA. PPADS was also under these conditions antagonistic with ADP-beta-S. In the 2nd part of the study, NMDA-induced currents were measured by whole-cell patch-clamp pipettes. ADP-beta-S caused a concentration-dependent inhibition of the responses to NMDA. PPADS alone did not alter the NMDA-currents but again antagonized the action of ADP-beta-S; 2'-deoxy-N(6)-methyladenosine-3',5'-diphosphate (MRS 2179) also abolished the NMDA effect. The ADP-beta-S-induced inhibition persisted in the presence of tetrodotoxin (TTX) or guanosine 5'-O-(3-thiodiphosphate) (GDP-beta-S) applied to the external medium and the pipette solution, respectively. The 8-cyclopentyl-1,3-dipropylxanthine (DPCPX) moderately decreased the ADP-beta-S effect. The inhibitory function of ADP-beta-S on EPSPs and the interaction with PPADS was observed also in layer V pyramidal neurons of the parietal somatosensory cortex. In conclusion, metabotropic P2Y(1) receptors appear to exert a new modulatory influence on fast excitatory amino acid transmission in the cerebral cortex.
Collapse
Affiliation(s)
- Julia Luthardt
- Rudolf-Boehm-Institute of Pharmacology and Toxicology, University of Leipzig, Haertelstrasse 16-18, D-04107, Leipzig, Germany
| | | | | | | | | | | |
Collapse
|
38
|
Wirkner K, Köles L, Thümmler S, Luthardt J, Poelchen W, Franke H, Fürst S, Illes P. Interaction between P2Y and NMDA receptors in layer V pyramidal neurons of the rat prefrontal cortex. Neuropharmacology 2002; 42:476-88. [PMID: 11955519 DOI: 10.1016/s0028-3908(01)00199-x] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
In the first part of this study, monosynaptic excitatory postsynaptic potentials (EPSPs) in layer V of the rat prefrontal cortex were evoked by electrical stimulation of layer I. Recordings by intracellular sharp microelectrodes showed that EPSPs were concentration-dependently facilitated by the P2 receptor antagonistic ATP analogue 2-methylthio ATP (2-MeSATP), while ATP itself depressed the synaptic potentials. The inhibitory effect of ATP turned into facilitation in the presence of the adenosine A(1) receptor antagonist DPCPX. The 2-MeSATP-induced potentiation of EPSP amplitudes were prevented by the P2 receptor antagonists PPADS and Suramin. The EPSP was almost abolished by coapplication of the NMDA receptor antagonist AP-5 and the AMPA/kainate receptor antagonist CNQX. After blockade of the NMDA receptor-mediated part of the EPSP by AP-5, the stimulatory effect of 2-MeSATP disappeared. When NMDA or AMPA were pressure-applied onto pyramidal cells, only the NMDA-induced depolarization was potentiated by 2-MeSATP. In the second part of the study, NMDA-induced currents were measured by whole-cell patch-clamp pipettes. ATP, 2-MeSATP, UDP and UTP potentiated the response to NMDA, while ADP-beta-S was inactive. PPADS antagonized the effect of ATP. Synaptic isolation of pyramidal neurons by a Ca(2+)-free medium or tetrodotoxin did not alter the effect of ATP which, however, was markedly depressed when GTP in the micropipette was replaced by GDP-beta-S. These observations suggest that in layer V pyramidal neurons of the prefrontal cortex postsynaptically localized P2Y receptors interact with NMDA receptor-channels.
Collapse
Affiliation(s)
- Kerstin Wirkner
- Rudolf-Boehm-Institute of Pharmacology and Toxicology, University of Leipzig, Härtelstr. 16-18, D-04107, Leipzig, Germany.
| | | | | | | | | | | | | | | |
Collapse
|